documents incorporated reference parts ii iii portions registrants annual report shareholders fiscal year annual report parts iii portions registrants proxy statement annual meeting shareholders filed within days close registrants fiscal year proxy statementitem part business general segments business geographic areas raw materials patents trademarks seasonality competition research development environment regulation available information risk factors b unresolved staff comments properties legal proceedings mine safety disclosures executive officers registrant part ii market registrants common equity related stockholder matters issuer purchases equity securities selected financial data managements discussion analysis financial condition results operation quantitative qualitative disclosures market risk financial statements supplementary data changes disagreements accountants accounting financial disclosure controls procedures b information part iii directors executive officers corporate governance executive compensation security ownership certain beneficial owners management related stockholder matters certain relationships related transactions director independence principal accountant fees services part iv exhibits financial statement schedules schedule ii valuation qualifying accounts signatures report independent registered public accounting firm financial statement schedule exhibit index table contents part item business general johnson johnson subsidiaries company approximately employees worldwide engaged research development manufacture sale broad range products health care field johnson johnson holding company operating companies conducting business virtually countries world companys primary focus products related human health wellbeing johnson johnson incorporated state new jersey companys structure based principle decentralized management executive committee johnson johnson principal management group responsible strategic operations allocation resources company committee oversees coordinates activities consumer pharmaceutical medical devices diagnostics business segments line principle decentralized management senior management groups us international operating companies responsible strategic plans well daytoday operations companies subsidiary within business segments exceptions managed citizens country located segments business company organized three business segments consumer pharmaceutical medical devices diagnostics additional information required item incorporated herein reference narrative tabular descriptions segments operating results caption managements discussion analysis results operations financial condition note segments business geographic areas notes consolidated financial statements annual report filed exhibit report consumer consumer segment includes broad range products used baby care skin care oral care wound care womens health care fields well nutritional overthecounter pharmaceutical products wellness prevention platforms baby care franchise includes johnsons baby line products major brands skin care franchise include aveeno clean clear johnsons adult neutrogena roc lubriderm dabao vendme product lines brands oral care franchise include listerine rembrandt oral care lines well reach interdental products wound care franchise includes bandaid brand adhesive bandages neosporin first aid products major brands womens health franchise carefree pantiliners ob tampons stayfree sanitary protection products principal nutritional line splenda calorie sweetener overthecounter medicines include broad family tylenol acetaminophen products sudafed cold flu allergy products zyrtec allergy products motrin ib ibuprofen products pepcid ac acid controller products marketed general public sold retail outlets distributors throughout world pharmaceutical pharmaceutical segment includes products following areas antiinfective antipsychotic contraceptive gastrointestinal hematology immunology infectious diseases neurology oncology pain management thrombosis vaccines products distributed directly retailers wholesalers health care professionals prescription use key products pharmaceutical segment include remicade infliximab treatment number immunemediated inflammatory diseases stelara ustekinumab treatment adults moderate severe plaque psoriasis simponi golimumab treatment adults moderate severe rheumatoid arthritis active psoriatic arthritis active ankylosing spondylitis velcade bortezomib treatment multiple myeloma zytiga abiraterone acetate treatment metastatic castrationresistant prostate cancer prezista darunavir intelence etravirine edurant rilpivirine treatments hivaids incivo telaprevir treatment hepatitis c nucynta er tapentadol extended release tablets treatment moderate severe chronic pain adults neuropathic pain associated diabetic peripheral neuropathy adults invega sustenna paliperidone palmitate acute maintenance treatment schizophrenia adults invega paliperidone extendedrelease tablets treatment schizophrenia schizoaffective disorder risperdal consta risperidone treatment management bipolar disorder schizophrenia xarelto rivaroxaban oral anticoagulant prevention thrombosis following total hip knee replacement surgery prevention stroke patients atrial fibrillation treatment pulmonary embolism pe deep vein thrombosis dvt reduce risk recurrence dvt pe following initial six months treatment acute venous thromboembolism procrit epoetin alfa sold outside us eprex stimulate red blood cell production levaquin levofloxacin treatment bacterial infectionstable contents concerta methylphenidate hcl extendedrelease tablets cii treatment attention deficit hyperactivity disorder aciphexpariet proton pump inhibitor comarketed eisai inc duragesic fentanyl transdermal system cii sold outside us durogesic treatment chronic pain offers novel delivery system medical devices diagnostics medical devices diagnostics segment includes broad range products used principally professional fields physicians nurses hospitals clinics include products treat cardiovascular disease orthopaedic neurological products blood glucose monitoring insulin delivery products general surgery biosurgical energy products professional diagnostic products infection prevention products disposable contact lenses products distributed wholesalers hospitals retailers directly surgical supply distributors geographic areas business johnson johnson conducted operating companies located countries including united states sell products virtually countries throughout world products made sold international business include many described segments business consumer pharmaceutical medical devices diagnostics however principal markets products methods distribution international business vary country culture products sold international business include developed united states also developed subsidiaries abroad investments activities countries outside united states subject higher risks comparable us activities investment commercial climate may influenced restrictive economic policies political uncertainties raw materials raw materials essential company 's business generally readily available multiple sources exceptions temporary unavailability raw materials would likely material adverse effect financial results company patents trademarks company 's subsidiaries made practice obtaining patent protection products processes possible licensed number patents relating products manufacturing processes aggregate believed material importance company operation businesses sales companys largest product remicade infliximab accounted approximately company 's total revenues fiscal accordingly patents related product believed material company june levaquin lost market exclusivity became subject generic competition united states sales levaquin united states declined approximately compared companys subsidiaries made practice selling products trademarks obtaining protection trademarks available means trademarks protected registration united states countries products marketed company considers trademarks aggregate material importance operation businesses seasonality worldwide sales reflect significant degree seasonality however spending heavier fourth quarter year quarters reflects increased spending decisions principally advertising research development activity competition product lines company 's subsidiaries compete companies locally globally throughout world competition exists product lines without regard number size competing companies involved competition research involving development improvement new existing products processes particularly significant development new innovative products important companys success areas business also includes protecting companys portfolio intellectual property competitive environment requires substantial investments continuing research maintaining sales forces addition development maintenance customer demand companys consumer products involves significant expenditures advertising promotion table contents research development research activities represent significant part companys businesses research development expenditures relate processes discovering testing developing new products improving existing products well demonstrating product efficacy regulatory compliance prior launch company remains committed investing research development aim delivering high quality innovative products worldwide costs research development activities amounted billion billion billion fiscal years respectively major research facilities located united states also belgium brazil canada china france germany india israel japan netherlands singapore switzerland united kingdom environment company subject variety us international environmental protection measures company believes operations comply material respects applicable environmental laws regulations companys compliance requirements past year expected material effect upon capital expenditures cash flows earnings competitive position regulation companys businesses subject varying degrees governmental regulation countries operations conducted general trend toward increasingly stringent regulation united states drug device diagnostics cosmetic industries long subject regulation various federal state agencies primarily product safety efficacy manufacturing advertising labeling safety reporting exercise broad regulatory powers us food drug administration fda continues result increases amounts testing documentation required fda clearance new drugs devices corresponding increase expense product introduction similar trends also evident major markets outside united states costs human health care continue subject study investigation regulation governmental agencies legislative bodies around world united states attention focused drug prices profits programs encourage doctors write prescriptions particular drugs recommend use purchase particular medical devices payers become potent force market place increased attention paid drug medical device pricing appropriate drug medical device utilization quality costs health care following us supreme court decision june upholding patient protection affordable care act aca increase pace regulatory issuances us government agencies designated carry extensive requirements aca positive negative impacts us healthcare industry much remaining uncertain various provisions aca ultimately affect industry regulatory agencies whose purview company operates administrative powers may subject actions product withdrawals recalls seizure products civil criminal sanctions cases companys subsidiaries may deem advisable initiate product recalls addition business practices health care industry come increased scrutiny particularly united states government agencies state attorneys general resulting investigations prosecutions carry risk significant civil criminal penalties available information companys main corporate website address wwwjnjcom copies companys quarterly reports form q annual report current reports form k filed furnished us securities exchange commission sec amendments foregoing provided without charge shareholder submitting written request secretary principal executive offices company calling companys sec filings also available companys website wwwinvestorjnjcomgovernancematerialscfm soon reasonably practicable electronically filed furnished sec sec filings also available secs website wwwsecgov addition written charters audit committee compensation benefits committee nominating corporate governance committee regulatory compliance government affairs committee science technology sustainability committee board directors companys principles corporate governance policy business conduct employees code business conduct ethics members board directors executive officers corporate governance materials available wwwinvestorjnjcomgovernancematerialscfm website address provided without charge shareholder submitting written request provided table contents item risk factors important factors could cause companys actual results differ companys expectations forwardlooking statements report set forth exhibit report item b unresolved staff comments applicable item properties company 's subsidiaries operate manufacturing facilities occupying approximately million square feet floor space manufacturing facilities used industry segments companys business approximately follows square feet segment thousands consumer pharmaceutical medical devices diagnostics worldwide total within united states facilities used consumer segment pharmaceutical segment medical devices diagnostics segment companys manufacturing operations outside united states often conducted facilities serve one business segment locations manufacturing facilities major geographic areas world follows square feet geographic area number facilities thousands united states europe western hemisphere excluding us africa asia pacific worldwide total addition manufacturing facilities discussed johnson johnson subsidiaries maintain numerous office warehouse facilities throughout world research facilities also discussed item business research development company 's subsidiaries generally seek manufacturing facilities although principally locations abroad leased office warehouse facilities often leased company committed maintaining properties good operating condition repair facilities well utilized mcneilppc inc continues operate consent decree signed fda governs certain mcneil consumer healthcare manufacturing operations mcneilppc inc continues operate manufacturing facilities las piedras puerto rico lancaster pennsylvania however production volumes facilities continue impacted additional review approval processes required consent decree company expects continue throughout plants operating consent decree produce simplified portfolio focused key brands fort washington pennsylvania manufacturing site operation time mcneil continues work resiting products previously produced fort washington facility facilities discussion matter found heading government proceedings mcneil consumer healthcare note legal proceedings notes consolidated financial statements annual report filed exhibit report information regarding lease obligations see note rental expense lease commitments notes consolidated financial statements annual report filed exhibit report segment information additions property plant equipment contained note segments business geographic table contents areas notes consolidated financial statements annual report filed exhibit report item legal proceedings information set forth note legal proceedings notes consolidated financial statements annual report incorporated herein reference filed exhibit report addition johnson johnson subsidiaries time time party government investigations inspections proceedings relating environmental matters including compliance applicable environmental laws connection routine inspection subsidiary 's manufacturing facility california department toxic substances control department alleged violation regulations dealing handling certain wastes company believes adequate defenses allegations exist presently discussions department regarding validity allegations although company predict ultimate outcome proceeding may brought regarding matters company expects matter resolved without significant penalties adverse impact company item mine safety disclosures applicable executive officers registrant listed executive officers company february unless otherwise indicated employee company held position indicated past five years family relationships executive officers arrangement understanding executive officer person pursuant executive officer selected annual meeting board directors executive officers elected board hold office one year respective successors elected qualified earlier resignation removal information regard directors company including information alex gorsky incorporated herein reference material captioned election directors proxy statement name age position dominic j caruso member executive committee vice president finance chief financial officera peter fasolo member executive committee vice president global human resources b alex gorsky chairman board directors chairman executive committee chief executive officer sandra e peterson member executive committee group worldwide chairmanc paulus stoffels member executive committee chief scientific officer worldwide chairman pharmaceuticals groupd michael h ullmann member executive committee vice president general counsele mr j caruso joined company company acquired centocor inc time acquisition senior vice president finance centocor mr caruso named vice president finance orthomcneil pharmaceutical inc subsidiary company vice president group finance companys medical devices diagnostics group mr caruso named vice president companys group finance organization mr caruso became member executive committee vice president finance chief financial officer b dr p fasolo joined company vice president worldwide human resources cordis corporation subsidiary company named vice president global talent management company left johnson johnson join kohlberg kravis roberts co chief talent officer dr fasolo returned company september vice president global human resources january became member executive committee c ms e peterson joined company december group worldwide chairman member executive committee responsibility consumer group companies johnson johnson supply chain information technology prior joining johnson johnson ms peterson extensive global career healthcare consumer goods consulting recently chairman chief executive officer bayer table contents cropscience ag germany previously serving president chief executive officer bayer medical care president bayer healthcare ag 's diabetes care division joining bayer ms peterson held number leadership roles medco health solutions previously known merck medco among responsibilities application information technology healthcare systems dr p stoffels joined company acquisition virco tibotec chief executive officer virco chairman tibotec appointed company group chairman global virology led development prezista intelence leading products treatment hiv assumed role company group chairman pharmaceuticals responsibility worldwide research development cns internal medicine franchises dr stoffels appointed global head research development pharmaceuticals became worldwide chairman pharmaceuticals group responsibility research development business development global strategy innovation october dr stoffels appointed chief scientific officer member executive committee e mr h ullmann joined company corporate attorney law department appointed corporate secretary served role time also held various management positions law department named general counsel medical devices diagnostics group mr ullmann appointed vice president general counsel member executive committee january part ii item market registrants common equity related stockholder matters issuer purchases equity securities february record holders common stock company additional information called item incorporated herein reference material captions managements discussion analysis results operations financial condition liquidity capital resources share repurchase dividends information common stock market prices note common stock stock option plans stock compensation agreements notes consolidated financial statements shareholder return performance graphs supporting schedules annual report filed exhibit report item security ownership certain beneficial owners management related stockholder matters equity compensation plan information report issuer purchases equity securities following table provides information respect common stock purchases company fiscal fourth quarter pursuant accelerated stock repurchase agreements connection acquisition synthes inc company made purchases common stock open market fiscal fourth quarter repurchases represent stockforstock option exercises settled fiscal fourth quarter maximum number total number shares approximate dollar units purchased value shares part publicly units may yet total number avg price announced plans purchased period shares purchased paid per share programs plans programs october october october november november december total item selected financial data information called item incorporated herein reference summary operations statistical data supporting schedules annual report filed exhibit report item managements discussion analysis financial condition results operations information called item incorporated herein reference narrative tabular material caption managements discussion analysis results operations financial condition annual report filed exhibit report table contents item quantitative qualitative disclosures market risk information called item incorporated herein reference material caption managements discussion analysis results operations financial condition liquidity capital resources financing market risk note summary significant accounting policies financial instruments notes consolidated financial statements annual report filed exhibit report item financial statements supplementary data information called item incorporated herein reference audited consolidated financial statements notes thereto material caption report independent registered public accounting firm annual report filed exhibit report item changes disagreements accountants accounting financial disclosure applicable item controls procedures disclosure controls procedures end period covered report company evaluated effectiveness design operation disclosure controls procedures companys disclosure controls procedures designed ensure information required disclosed company reports files submits exchange act recorded processed summarized reported within time periods specified secs rules forms disclosure controls procedures include without limitation controls procedures designed ensure information required disclosed company reports files submits exchange act accumulated communicated companys management including principal executive principal financial officers persons performing similar functions appropriate allow timely decisions regarding required disclosure alex gorsky chairman chief executive officer dominic j caruso chief financial officer reviewed participated evaluation based evaluation messrs gorsky caruso concluded end period covered report companys disclosure controls procedures effective managements report internal control financial reporting information called item incorporated herein reference material caption managements report internal control financial reporting annual report filed exhibit report changes internal control financial reporting fiscal quarter ended december changes companys internal control financial reporting identified connection evaluation required rules exchange act materially affected reasonably likely materially affect companys internal control financial reporting item b information applicable part iii item directors executive officers corporate governance information called item incorporated herein reference material captions item election directors stock ownership section compliance section beneficial ownership reporting compliance discussion audit committee caption corporate governance standing board committees proxy statement material caption executive officers registrant part report companys policy business conduct covers employees including chief executive officer chief financial officer controller meets requirements sec rules promulgated section sarbanesoxley act policy business conduct available companys website wwwinvestorjnjcomgovernancepoliciescfm copies available shareholders without charge upon written request secretary companys principal executive offices substantive amendment policy business conduct waiver policy granted chief executive officer chief financial officer controller posted companys website wwwinvestorjnjcomgovernancecfm within five business days retained website least one year addition company adopted code business conduct ethics members board directors executive officers code business conduct ethics members board directors executive officers available table contents companys website wwwinvestorjnjcomgovernancepoliciescfm copies available shareholders without charge upon written request secretary companys principal executive offices substantive amendment code waiver code granted member board directors executive officer posted companys website wwwinvestorjnjcomgovernancecfm within five business days retained website least one year item executive compensation information called item incorporated herein reference material captions corporate governance item election directors director compensation compensation committee report compensation discussion analysis executive compensation proxy statement material incorporated herein reference material caption compensation committee report proxy statement shall deemed furnished filed report shall deemed incorporated reference filing securities act amended securities exchange act amended result furnishing except extent registrant specifically incorporates reference item security ownership certain beneficial owners management related stockholder matters additional information called item incorporated herein reference material captions stock ownership section compliance proxy statement note common stock stock option plans stock compensation agreements notes consolidated financial statements annual report filed exhibit report equity compensation plan information following table provides certain information december concerning shares companys common stock may issued existing equity compensation plans number securities issued upon weighted average number securities exercise exercise price remaining available outstanding options outstanding options future issuance equity plan category rights rights compensation plans equity compensation plans approved security holders equity compensation plans approved security holders total included category following equity compensation plans approved companys shareholders stock option plan longterm incentive plan longterm incentive plan included category shares common stock company issuable one equity compensation plan assumed company upon acquisition scios inc time acquisition options acquire equity acquired company replaced options acquire common stock company stock options equity awards type made plan since assumption plan company stock options equity awards type made plan future shares issued plan approved shareholders scios scios nonofficer stock option plan column excludes shares reflected column number securities issued upon exercise outstanding options rights longterm incentive plan expired april options restricted shares granted subsequent date longterm incentive plan item certain relationships related transactions director independence information called item incorporated herein reference material captions transactions related persons corporate governance director independence proxy statement table contents item principal accountant fees services information called item incorporated herein reference material caption ratification appointment independent registered public accounting firm proxy statement part iv item exhibits financial statement schedules following documents filed part report financial statements following audited consolidated financial statements notes thereto material caption report independent registered public accounting firm annual report incorporated herein reference filed exhibit report consolidated balance sheets end fiscal years consolidated statements earnings fiscal years consolidated statements comprehensive income fiscal years consolidated statements equity fiscal years consolidated statements cash flows fiscal years notes consolidated financial statements report independent registered public accounting firm financial statement schedules schedule ii valuation qualifying accounts schedules listed omitted required applicable exhibits required filed item l regulation sk information called item incorporated herein reference exhibit index report table contents johnson johnson subsidiaries schedule ii valuation qualifying accounts fiscal years ended december january january dollars millions balance balance beginning end period accruals paymentsother period accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total includes reserve customer rebates million million million december january january respectively table contents signatures pursuant requirements section securities exchange act registrant duly caused report signed behalf undersigned thereunto duly authorized date february johnson johnson registrant gorsky gorsky chairman board directors chief executive officer pursuant requirements securities exchange act report signed following persons behalf registrant capacities dates indicated signature title date gorsky chairman board directors february gorsky chief executive officer director principal executive officer j caruso chief financial officer principal financial officer february j caruso j cosgrove controller principal accounting officer february j cosgrove coleman director february coleman j g cullen director february j g cullen e l davis director february e l davis e johns director february e johns table contents signature title date l lindquist director february l lindquist mulcahy director february mulcahy l f mullin director february l f mullin w perez director february w perez c prince director february c prince satcher director february satcher e washington director february e washington r williams director february r williams table contents report independent registered public accounting firm financial statement schedule board directors johnson johnson audits consolidated financial statements effectiveness internal control financial reporting referred report dated february appearing annual report shareholders johnson johnson report consolidated financial statements incorporated reference annual report also included audit financial statement schedule listed item opinion financial statement schedule presents fairly material respects information set forth therein read conjunction related consolidated financial statements pricewaterhousecoopers llp new york new york february table contents exhibit index reg sk exhibit table description item exhibit ia restated certificate incorporation effective april incorporated herein reference exhibit registrants form k annual report year ended december ib certificate amendment restated certificate incorporation company effective may incorporated herein reference exhibit registrants annual report year ended january ic certificate amendment restated certificate incorporation company effective may incorporated herein reference exhibit aiii registrants annual report year ended december id certificate amendment restated certificate incorporation company effective may incorporated herein reference exhibit registrants form q quarterly report quarter ended july ie certificate amendment restated certificate incorporation company effective april incorporated herein reference exhibit registrants form q quarterly report quarter ended april ii bylaws company amended effective april incorporated herein reference exhibit registrants form k current report filed april upon request securities exchange commission registrant furnish copy instruments defining rights holders longterm debt registrant stock option plan nonemployee directors incorporated herein reference exhibit registrants annual report year ended december b stock option plan amended incorporated herein reference exhibit b registrant 's annual report year ended january c longterm incentive plan incorporated herein reference exhibit registrants registration statement filed commission may file form restricted shares nonemployee directors longterm incentive plan incorporated herein reference exhibit registrants form k current report filed august e form stock option certificate restricted share unit certificate performance share unit certificate longterm incentive plan incorporated herein reference exhibits registrants form k current report filed january f longterm incentive plan incorporated herein reference appendix registrants proxy statement filed commission march g form stock option certificate restricted share unit certificate performance share unit certificate longterm incentive plan incorporated herein reference exhibits registrants form q quarterly report filed may h executive incentive plan amended incorporated herein reference exhibit f registrants annual report year ended december domestic deferred compensation certificate extra compensation plan incorporated herein reference exhibit g registrants annual report year ended december j amendments certificate extra compensation plan effective january incorporated herein reference exhibit j registrants annual report year ended december k certificates longterm performance plan incorporated herein reference exhibit registrants form q quarterly report quarter ended september l amended restated deferred fee plan directors incorporated herein reference exhibit k registrant 's annual report year ended january executive income deferral plan amended restated incorporated herein reference exhibit registrants form q quarterly report quarter ended september table contents reg sk exhibit table description item exhibit n excess savings plan incorporated herein reference exhibit j registrants form k annual report year ended december amendments johnson johnson excess savings plan effective january incorporated herein reference exhibit p registrants annual report year ended december p excess benefit plan supplemental retirement plan incorporated herein reference exhibit h registrants annual report year ended january q amendments excess benefit plan johnson johnson affiliated companies effective january incorporated herein reference exhibit r registrants annual report year ended december r executive life plan agreement incorporated herein reference exhibit registrants annual report year ended january employment agreement dr paulus stoffels incorporated herein reference exhibit registrants form q quarterly report quarter ended september summary employment arrangements sandra e peterson filed document statement computation ratio earnings fixed charges filed document following sections annual report shareholders fiscal year incorporated reference report deemed filed management 's discussion analysis results operations financial condition audited consolidated financial statements supporting schedules summary operations statistical data supporting schedules shareholder return performance graphs filed document subsidiaries filed document consent independent registered public accounting firm filed document certification chief executive officer pursuant section sarbanesoxley act filed document b certification chief financial officer pursuant section sarbanesoxley act filed document certification chief executive officer pursuant section sarbanesoxley act furnished document b certification chief financial officer pursuant section sarbanesoxley act furnished document cautionary statement pursuant private securities litigation reform act safe harbor forwardlooking statements filed document xbrl extensible business reporting language following materials johnson johnsons annual report fiscal yearended december formatted extensive business reporting language xbrl consolidated balance sheets ii consolidated statements earnings iii consolidated statements comprehensive income iv consolidated statements equity v consolidated statements cash flows vi notes consolidated financial statements vii schedule ii valuation qualifying accounts management contract compensatory plan copy exhibits listed provided without charge shareholder submitting written request specifying desired exhibits secretary principal executive offices company exhibit employment agreement johnson johnson co peter fasolo ww vicepresident human resources one johnson johnson plaza new brunswick new jersey employer sandra e peterson old beach road tudor lodge newport rhode island employee employer employee hereinafter referred collectively parties individually party whereas employer corporation organized laws state new jersey united states america wishes hire employee indefinite term b employee desires work employer therefore parties agreed follows title job duties reporting relationship upon effective date employee shall employed employer shall title group worldwide chair serve executive committee member employer employee shall directly report chief executive officer ceo company employee shall responsible leading managing employer 's consumer supply chain business units employer chief executive officer right assign duties responsibilities employee commensurate employee 's title knowledge experience skills specified duties work location employee 's place work shall employer 's corporate office new brunswick new jersey employee 's duties may require employee regularly travel business locations united states abroad travel may include reasonably required weekends public holidays employment terms start date employment agreement atwill entered indefinite term anticipated first day employment start date november earlier parties may agree provided however employment agreement shall null void ab initio force effect employee unable obtain agreement current employer current employer allowing early cancellation contract service agreement service agreement current employer unable get release andor amendment post contractual noncompete obligations post employment restrictions manner reasonably satisfactory employer manner would permit commence employment consistent job responsibilities duties employment agreement parties agree use reasonable efforts negotiate employee 's departure current employer respect service agreement post employment restrictions employer agrees extend november start date december provided negotiations employee 's current employer regarding two conditions set forth continuing progressing provided employee starts employment employer within days preconditions set forth met later december employee agrees promptly inform employer current employer informs unwilling nego tiate provisions andor negotiations current employer terminated due impasse parties agree offer employment employment agreement expire prior december remain open long employee commences employment date unless parties mutually conclude current employer unwilling negotiate terms would legally permit employee commence employment employer consistent timing job responsibilities duties employment agreement salary employee 's starting base salary base salary shall us less applicable deductions shall payable biweekly consistent normal payroll practices employer employee considered merit increase base salary accordance employer 's normal cycle increased amount applicable shall thereafter employee 's base salary purposes employment agreement amount merit increase determined employer 's sole discretion based factors including market data internal equity individual performance business performance signon bonus employee shall also receive installment payments cash sign bonus totaling signon less applicable withholdings paid two cash installments described installment signon subject employee actively employed payout date first installment payment paid employee shortly employee 's start date second payment paid april may except provided last sentence paragraph subject employee remaining actively employed employer date payout employee voluntarily terminate employment good reason due disability defined company 's disability plan employment terminated employer cause prior first anniversary date second installment payment employee required reimburse employer full amount signon installment payments employee receive unpaid installment payment signon payable terminated without cause defined resigns good reason defined cause purposes employment agreement shall mean occurence following employee 's conviction plea guilty nolo contendere crime involving moral turpitude dishonesty fraud theft financial impropriety unethical business conduct felony nature whatsoever results incarceration criminal probation ii employee 's engagement conduct constitutes gross misconduct gross neglect willful failure perform material duties employee 's position iii employee 's material breach applicable rules policies andor practices employer including limited conduct would constitute group offense employer 's performance conduct standards policy violation employer 's policy business conduct iv employee 's material breach secrecy intellectual property noncompetition nonsolicitation agreement purposes agreement willful failure perform apply acts ommissions conducted employee good faith reasonable belief act omission best interests employer good reason purposes employment agreement means occurrence following without employee 's consent material adverse change employee 's title duties responsibilities including reporting responsibilities ii material reduction employee 's base salary iii relocation employee 's principal office miles office new brunswick new jersey apply customary business travel throughout us abroard associated role group worldwide chair required determined job duties section iv failure assign successor business contractual obligations employer employment agreement employer employee agree good reason shall exist unless employee provides employer written notice acts alleged constitute good reason within ninety days employee 's knowledge occurrence event employer fails cure acts within thirty days receipt notice curable employee must terminate employment within sixty days following expiration cure period termination account good reason rsu replacement award employee shall receive new hire restricted share unit rsu grant fair value compensate awards employee forfeiting upon leaving employment current employer number rsus determined dividing rsu fair value fair value per rsu employer 's common stock grant date defined number rsus rounded nearest whole share employee 's new hire grant processed granted date first business day month least days days following start date provided events long employee 's start date later december award granted later december grant date shall subject administered accordance terms employer 's ltip vesting subject terms accompanying award agreement award agreement grant shares vest three equal installments follows vest one year grant date vest two years grant date vest three years grant date employee understands agrees must active employee date vesting vest rsu shares severance first three years employment employer terminates employment agreement cause defined section employee terminates employment good reason defined section employee shall entitled cash lump sum severance payment severance equal weeks base salary less applicable deductions employee 's receipt severance subject execution general release claims within days termination date general release claims impose upon employee postemployment covenants beyond employee agreed prior termination employment continuing compliance existing post employment contractual obligations including confidentiality agreement nonsolicitation andor noncompetition agreement signed employee employer severance payable later days general release claims becomes irrevocable first three years employment employee 's eligibility severance shall governed terms conditions severance pay plan johnson johnson us affiliated companies effect time termination level executive committee member discretionary bonus remuneration except otherwise provided herein award bonuses longterm incentives forms voluntary additional remuneration shall determined accordance employer 's corporate executive compensation plans programs effect executive committee members subject terms conditions individual plans programs eligibility criteria well payment plan program determined employer sole discretion employer may modify repeal plans programs discretion time rights obligations employee plan program shall governed terms plan program amended time time individual bonus agreements employer employee award voluntary additional forms remuneration shall subject continued existence employment relationship employer employee employment agreement effect time remuneration paid except described section employee may deduce legal entitlements said plans programs except provided accordance terms thereof repeated awarding voluntary additional remuneration within scope said plans programs shall give rise entitlement future payments annual performance bonus based employee 's position group worldwide chair executive committee member employee 's annual bonus target opportunity annual base salary less applicable deductions performance year payable first quarter currently corporate executive plan effect executive employee 's level bonus paid cash shares employer 's common stock terms current plan shares awarded part annual performance bonus fully vest upon grant longterm incentive compensation based employee 's position employee 's current longterm incentive lti fair value target opportunity employee 's base salary performance year granted first quarter award comprised combination stock options rsus performance share units psus accordance employer 's executive compensation plans programs awards vest three years date grant compensation generally except provided herein respect employee 's sign bonus section replacement rsus section starting base salary performance year performance bonus lti compensation targets granting compensation well amount management 's sole discretion contingent upon employee 's individual performance performance employer performance criteria defined employer 's compensation plans employee 's length service year granted guidelines continued eligibility determined annually subject change year year continuation compensation program subject management 's discretion salary nonsalary compensation based guidelines eligibility well employee 's performance determined yearend employer results assessed paid granted first quarter following year employment employee eligible salary bonus lti compensation commensurate employees similarly situated employee 's title reporting level responsibilites individual tax obligations may arise based employee 's employment jurisdiction solely employee 's employer responsibility directly indirectly respect obligations including obligation pay reimburse gross payments employee benefit programs employee eligible participate current executive benefit programs current employee medical dental life accidental insurance coverage k plans pension plans commensurate employee 's position employee eligible participate employer 's medical benefit plan commencing start date expenses reimbursement travel expenses shall subject paid basis relevant policies parent governing expenses including johnson johnson global travel entertainment policy amended time time vacation employee entitled twenty days paid vacation per year employee 's total vacation floating holiday entitlement based employee 's start date prorated according current vacation holiday policy granting floating holidays management 's sole discretion announced annually relocation employee 's relocation administered accordance terms employer 's current relocation policy employee voluntarily terminate employment employment terminated cause defined section within months start date employee required reimbursethe employer affiliate relocation costs paid employee 's behalf employee understands agrees required sign employer 's relocation repayment agreement return signed employment agreement employee understands employment atwill relocation repayment agreement contract employment imply employee 's employment continue period time confer rights respect duration employment employee repayment obligation employment terminated without cause resigns good reason defined section confidentiality noncompetition nonsolicitation condition entering employment agreement employee enter abide employee secrecy intellectual property noncompetition nonsolicitation agreement attached hereto become effective start date employment application preemployment forms employee understands agrees must satisfactorily complete following prior start date background reference checks employer hereby confirms satisfied preplacement health evaluation including drug screen employment application employer 's background release form employer hereby confirms completed work authorization papers documentation assignment employer may sole discretion transfer assign employment agreement employee 's employment pursuant employment agreement affiliates employer case affiliate automatically become employee 's employer employee 's consent required transaction long affiliate assumes liabilities obligations duties employer contained employment agreement common ground program employer employs employee dispute resolution program common ground exclusive means attempting quickly resolve disputes employees employer parties agree program employment related claims may referred nonbinding mediation prior litigation information regarding common ground program provided attached brochure miscellaneous employment agreement policies rules employer constitute entire agreement understanding among parties respect employment employee employer shall supersede prior oral written agreements understandings parties relating hereto except otherwise agreed parties writing representation statement whatever form made employee connection employee 's employment incorporated employment agreement shall valid binding employer amendments employment agreement shall valid made writing provision employment agreement found competent authority void invalid unenforceable provision shall deemed deleted employment agreement remaining provisions employment agreement shall continue full force event employment agreement shall construed necessary amended way give effect approximate achieve result close legally possible result intended provision hereof determined void illegal unenforceable anything employment agreement contrary notwithstanding intended amounts payable employment agreement either exempt comply section internal revenue code amended regulations guidance interpretive authority issued thereunder collectively section subject employee payment additional tax penalty interest imposed section employment agreement interpreted basis consistent intent b extent reimbursement expenses provision inkind benefits employment agreement subject section amount expenses eligible reimbursement inkind benefits provided one calendar year shall affect amount expenses eligible reimbursement inkind benefits provided calendar year provided clause violated regard expenses reimbursed arrangement covered code section b solely expenses subject limit related period arrangement effect ii reimbursement expense shall made later december year following calendar year expense incurred iii employee 's right receive reimbursements inkind benefits shall subject liquidation exchange another benefit c employee specified employee within meaning treasury regulation section date employee 's separation service within meaning treas reg section ah payment benefit pursuant employment agreement account employee 's separation service extent payment constitutes nonqualified deferred compensation subject section required delayed pursuant section aabi code taking account exclusions applicable payment section shall made first business day expiration six months date employee 's separation service ii earlier date employee 's death delay period upon expiration delay period payments benefits delayed pursuant employment agreement whether would otherwise payable single sum installments absence delay paid reimbursed employee lump sum remaining payments benefits due employment agreement paid provided accordance normal payment dates specified herein notwithstanding provision employment agreement contrary purposes provision employment agreement providing payment amounts benefits upon following termination employment considered deferred compensation section references employee 's termination employment corollary terms employer shall construed refer employee 's separation service within meaning treas reg section ah employer whenever payments employment agreement made installments installment shall deemed separate payment purposes section whenever payment employment agreement specifies payment period reference number days eg payment made within thirty days following date termination actual date payment within specified period shall within sole discretion employer e extent amount payable employee subject employee entering release claims employer amount deferral compensation section amount could payable either two taxable years employee timing payment subject terms conditions another plan program agreement company otherwise satisfies section payments shall made applicable january later date earlier days date release becomes irrevocable later taxable year shall include payments otherwise would made date applicable law employment agreement subject new jersey law addendums agreements documents attached employment agreement amended time time form integral part employment agreement effective date agreement agreement effective later date preconditions employee 's employment met date parties employee signed executed agreement effective offer employment agreement governed section employer johnson johnson peter fasolo peter fasolo dated august worldwide vicepresident human resources employee sandra e peterson sandra e peterson sandra e peterson dated august addendums policy business conduct employee secrecy intellectual property noncompetition nonsolicitation agreement relocation repayment agreement performance standards conduct policyexhibit johnson johnson subsidiaries statement computation ratio earnings fixed charges dollars millions fiscal year ended january january december december january determination earnings earnings provision taxes income fixed charges less capitalized interest total earnings defined fixed charges estimated interest portion rent expense interest expense capitalization interest total fixed charges ratio earnings fixed charges ratio earnings fixed charges computed dividing sum earnings provision taxes income fixed charges fixed charges fixed charges represent interest expense interest capitalized amortization debt discount appropriate interest factor operating leasestable contents managements discussion analysis results operations financial condition organization business segments results operations analysis sales business segments analysis consolidated earnings provision taxes income liquidity capital resources information cautionary factors may affect future results audited consolidated financial statements consolidated balance sheets consolidated statements earnings consolidated statements comprehensive income consolidated statements equity consolidated statements cash flows notes consolidated financial statements report independent registered public accounting firm managements report internal control financial reporting supporting schedules summary operations statistical data shareholder return performance graphs johnson johnson annual report managements discussion analysis results operations financial condition organization business segments description company business segments johnson johnson subsidiaries company approximately employees worldwide engaged research development manufacture sale broad range products health care field company conducts business virtually countries world primary focus products related human health wellbeing company organized three business segments consumer pharmaceutical medical devices diagnostics consumer segment includes broad range products used baby care skin care oral care wound care womens health fields well nutritional overthecounter pharmaceutical products wellness prevention platforms products marketed general public sold retail outlets distributors throughout world pharmaceutical segment includes products following areas antiinfective antipsychotic contraceptive gastrointestinal hematology immunology infectious diseases neurology oncology pain management thrombosis vaccines products distributed directly retailers wholesalers health care professionals prescription use medical devices diagnostics segment includes broad range products distributed wholesalers hospitals retailers used principally professional fields physicians nurses hospitals clinics include products treat cardiovascular disease orthopaedic neurological products blood glucose monitoring insulin delivery products general surgery biosurgical energy products professional diagnostic products infection prevention products disposable contact lenses companys structure based upon principle decentralized management executive committee johnson johnson principal management group responsible strategic operations allocation resources company committee oversees coordinates activities consumer pharmaceutical medical devices diagnostics business segments product lines company competes companies locally globally throughout world competition exists product lines without regard number size competing companies involved competition research involving development improvement new existing products processes particularly significant development new innovative products important companys success areas business also includes protecting companys portfolio intellectual property competitive environment requires substantial investments continuing research maintaining sales forces addition development maintenance customer demand companys consumer products involves significant expenditures advertising promotion managements objectives company manages within strategic framework aimed achieving sustainable growth accomplish companys management operates business consistent certain strategic principles proven successful time end company participates growth areas human health care committed attaining leadership positions growth areas development high quality innovative products services new products introduced within past five years accounted approximately sales billion sales invested research development investment reflects managements commitment importance ongoing development new differentiated products services sustain longterm growth operating companies located countries company views principle decentralized management asset fundamental success broadly based business also fosters entrepreneurial spirit combining extensive resources large organization ability anticipate react quickly local market changes challenges company committed developing global business leaders achieve growth objectives businesses managed longterm order sustain leadership positions achieve growth provides enduring source value shareholders credo unifies management team companys dedicated employees achieving objectives provides common set values serve constant reminder companys responsibilities customers employees communities shareholders company believes basic principles along overall mission improving quality life people everywhere enable johnson johnson continue among leaders health care industry results operations analysis consolidated sales worldwide sales increased billion compared increase decrease sales changes consisted following johnson johnson annual report sales increasedecrease due volume price currency total sales us companies billion billion billion represents increase decreases sales international companies billion billion billion represents increases acquisition synthes inc net related divestiture increased total worldwide sales growth operational growth fiveyear compound annual growth rates worldwide us international sales respectively tenyear compound annual growth rates worldwide us international sales respectively sales europe experienced decline compared prior year including operational growth offset negative currency impact sales western hemisphere excluding us achieved growth compared prior year including operational growth negative currency impact sales asiapacific africa region achieved growth compared prior year including operational growth negative currency impact company customer represented total consolidated revenues us health care reform provisions patient protection affordable care act health care education reconciliation act beginning companies sold branded prescription drugs specified us government programs pay annual nontax deductible fee based allocation companys market share total branded prescription drug sales prior year fullyear impact selling marketing administrative expenses approximately million million current law beginning company required pay tax deductible excise tax imposed sale certain medical devices excise tax estimated million recorded cost products sold within statement earnings net trade sales impact health care reform legislation annual reduction approximately million million respectively due increase sales rebates discounts analysis sales business segments consumer segment consumer segment sales billion decrease included operational growth offset negative currency impact us consumer segment sales billion decrease international sales billion decrease included operational growth offset negative currency impact major consumer franchise sales change dollars millions vs vs otc pharmaceuticals nutritionals skin care baby care womens health oral care wound careother total consumer sales overthecounter otc pharmaceuticals nutritionals franchise sales billion decrease sales us decreased primarily due lower sales analgesics result supply constraints competitive pressures nutritional products strong growth upper respiratory digestive health analgesics products outside us offset negative currency mcneilppc inc continues operate consent decree signed us food drug administration fda governs certain mcneil consumer healthcare manufacturing operations mcneil continues johnson johnson annual report operate manufacturing facilities las piedras puerto rico lancaster pennsylvania however production volumes facilities continue impacted additional review approval processes required consent decree company expects continue throughout plants operating consent decree produce simplified portfolio focused key brands fort washington pennsylvania manufacturing site operation time mcneil continues work resiting products previously produced fort washington facility facilities skin care franchise sales billion decrease increased sales neutrogena productsin us offset competition economic conditions outside us baby care franchise sales billion decrease decline us sales impact negative currency partially offset increased sales haircare wipes outside us womens health franchise sales billion decrease primarily due impact divestiture certain brands oral care franchise sales flat compared prior year increased sales listerine products outside us partially offset competitive pressures usthe wound careother franchise sales billion decrease due divestitures competitive pressures negative currency impacted franchises consumer segment sales billion increase operational decline offset positive currency impact us consumer segment sales billion decrease international sales billion increase included operational growth positive currency impact johnson johnson annual report pharmaceutical segment pharmaceutical segment achieved sales billion representing increase prior year operational growth negative currency impact us sales billion increase international sales billion increase included operational growth negative currency impact major pharmaceutical therapeutic area sales change dollars millions vs vs total immunology remicade simponi stelara immunology total infectious diseases intelence levaquinfloxin prezista infectious diseases total neuroscience concertamethylphenidate invega invega sustennaxeplion risperdal consta neuroscience total oncology doxilcaelyx velcade zytiga oncology total aciphexpariet procriteprex total pharmaceutical sales prior year amounts reclassified conform current year presentation percentage greater immunology products achieved sales billion representing increase compared prior year increased sales simponi golimumab remicade infliximab primarily due market growth impact agreement merck co inc merck effective july distribution rights remicade simponi certain territories relinquished company merck additional contributors increase sales stelara ustekinumab infectious disease products achieved sales billion representing increase compared prior year major contributors incivo telaprevir continued momentum market share growth prezista darunavir edurant rilpivirine intelence etravirine partially offset lower sales levaquin levofloxacinfloxin ofloxacin due loss market exclusivity us june neuroscience products sales billion decline compared prior year growth impacted generic competition concertamethylphenidate razadyne galantamine risperdalrisperidone duragesicfentanyl transdermal fentanyl transdermal system decline company 's longacting injectable johnson johnson annual report antipsychotic risperdal constarisperidone offset strong sales invega sustennaxeplion paliperidone palmitate invega paliperidone palmitate company 's us supply distribution agreement watson laboratories inc distribute authorized generic version concerta became effective may original concerta patent expired parties received approval fda manufacture market generic version concerta another generic version concerta launched december result reduction concerta sales oncology products achieved sales billion representing increase compared prior year growth primarily due sales zytigaabiraterone acetate velcade bortezomib growth partially offset lower sales doxildoxorubicin hci liposome injectioncaelyxpegylated liposomal doxorubicin hydrochloride due supply constraints company 's thirdparty manufacturer company working restore reliable supply doxilcaelyx full access us restored alternate manufacturing approach approved european union eu japan late canada january european union caelyx managed access program put place ensure patients complete full course treatment remain place full supply caelyx restored february fda approved generic version doxil pharmaceutical sales billion decline compared prior year primarily due divestitures lower sales aciphexparietrabeprazole sodium eprex epoetin alfa primarily due impact generic competition results partially offset sales growth xareltorivaroxaban company received several regulatory approvals including us approval new mg tablet prezista darunavir daily oral administration treatment human immunodeficiency virus hiv treatmentnaive treatmentexperienced adult patients darunavir resistance associated mutations fda approval expanded use xareltorivaroxaban treat deepvein thrombosis dvt pulmonary embolism pe reduce risk recurrent dvt pe following initial treatment fda granted accelerated approval sirturo bedaquiline tablets treatment pulmonary multidrug resistant tuberculosis part combination therapy adults fda approved supplemental new drug application nda nucynta er tapentadol extendedrelease tablets oral analgesic taken twice daily management neuropathic pain associated diabetic peripheral neuropathy adults fda european commission also approved expanded indication zytiga abiraterone acetate combination prednisone allowing use chemotherapy treatment metastatic castrationresistant prostate cancer addition european commission approved marketing authorizations dacogen decitabine treatment adult patients age years newly diagnosed de novo secondary acute myeloid leukemia candidates standard induction chemotherapy subcutaneous administration velcade bortezomib treatment multiple myeloma company submitted several new drug applications including nda fda marketing authorization application maa european medicines agency ema seeking approval use canagliflozin oral oncedaily selective sodium glucose cotransporter sglt inhibitor treatment adult patients type diabetes nda seeking approval fixeddose therapy combining canagliflozin immediate release metformin treat patients type diabetes additional submissions included supplemental biologics license application fda type ii variation ema requesting approval stelara ustekinumab treatment adult patients active psoriatic arthritis biologics license application fda requesting approval investigational intravenous formulation antitumor necrosis factor tnfalpha simponi golimumab treatment adults moderately severely active rheumatoid arthritis addition supplemental biologics license application submitted fda type ii variation submitted ema requesting approval simponi golimumab treatment moderately severely active ulcerative colitis adult patients inadequate response conventional therapy including corticosteroids mercaptopurine mp azathioprine aza intolerant medical contraindications therapies finally maa submitted ema seeking conditional approval use bedaquiline tmc oral treatment used part combination therapy pulmonary multidrug resistant tuberculosis adults pharmaceutical segment sales billion increase operational growth positive currency impact us sales billion decrease international sales billion increase included operational growth positive currency impact medical devices diagnostics segment medical devices diagnostics segment achieved sales billion representing increase prior year operational growth negative currency impact us sales billion increase compared prior year international sales billion increase prior year operational growth negative currency impact acquisition synthes inc net related divestiture increased total sales growth operational growth medical devices diagnostics segment johnson johnson annual report major medical devices diagnostics franchise sales change dollars millions vs vs orthopaedics surgical care vision care diabetes care specialty surgery diagnostics cardiovascular care infection preventionother total medical devices diagnostics sales prior year amounts reclassified conform current year presentation orthopaedics franchise achieved sales billion increase prior year growth primarily due sales newly acquired products synthes inc sales joint reconstruction mitek sports medicine products sales impacted divestitures surgical instruments business codman shurtleff inc fiscal fourth quarter divestiture certain rights assets related depuy trauma business positive impact orthopaedics franchise total sales growth operational growth due newly acquired products synthes inc net related trauma business divestiture surgical care franchise sales billion decrease prior year lower sales mechanical breast care pelvic floor products partially offset increased sales sutures endoscopy products success echelon flex powered endopath stapler vision care franchise achieved sales billion increase prior year growth driven acuvue trueye day acuvue moist astigmatism day acuvue moist diabetes care franchise sales billion decrease versus prior year sales growth asia latin america offset negative impact currency specialty surgery franchise achieved sales billion increase prior year incremental sales acquisition sterilmed inc sales biosurgery products international sales energy products major contributors growth diagnostics franchise sales billion decline versus prior year decline primarily due lower sales donor screening due competitive pressures divestiture rhogam business third quarter january company announced exploring strategic alternatives orthoclinical diagnostics business including possible divestiture cardiovascular care franchise sales billion decline versus prior year sales impacted companys decision exit drugeluting stent market second quarter lower sales endovascular products impacted competitive launches disruption supply resolved late third quarter decline sales partially offset strong growth biosense webster 's electrophysiology business primarily due success thermocool catheter launches infection preventionother franchise achieved sales billion increase prior year primarily due growth advanced sterilization business medical devices diagnostics segment achieved sales billion representing increase prior year operational growth positive currency impact us sales billion decrease compared prior year international sales billion increase prior year operational growth positive currency impact analysis consolidated earnings provision taxes income consolidated earnings provision taxes income increased billion billion compared billion increase earnings provision taxes income favorable due increased gross profit billion billion decrease selling marketing administrative expenses due cost containment initiatives across many businesses lower litigation expense billion lower charges billion related depuy asr hip program versus prior year partially offset billion charges attributable asset writedowns impairment inprocess research development primarily related crucell vaccine business discontinuation phase iii clinical development bapineuzumab iv billion integration currency costs related acquisition synthes inc versus prior year included billion restructuring charge net johnson johnson annual report inventory writeoffs included cost products sold related cardiovascular care business additionally included higher gains divestitures items billion recorded income expense net decrease compared primarily due costs associated litigation includes product liability impact otc depuy asr hip recalls restructuring expense related cardiovascular care business additionally investment spending fee branded pharmaceutical products incurred due us health care reform legislation integration costs including inventory stepup charge associated acquisition crucell contributed decrease earnings partially offset gains divestitures percent sales consolidated earnings provision taxes income versus cost products sold selling marketing administrative expenses cost products sold selling marketing administrative expenses percent sales follows sales cost products sold percent point increase prior year selling marketing administrative expenses percent point decreaseincrease prior year cost products sold percent sales increased compared prior year primarily result amortization inventory stepup charge billion amortization intangibles related synthes inc acquisition billion ongoing remediation costs mcneil otc business decrease percent sales selling marketing administrative expenses compared prior year primarily due cost containment initiatives across many businesses prior year period included higher investment spending pharmaceutical business new products cost products sold percent sales increased compared prior year primarily attributable ongoing remediation costs mcneil otc business inventory writeoffs due restructuring cardiovascular care business addition lower margins integration costs including inventory stepup charge associated acquisition crucell negatively impacted cost products sold percent sales selling marketing administrative expenses increased compared prior year primarily due investment spending well fee branded pharmaceutical products incurred due us health care reform legislation research development expense research development expense segment business follows dollars millions amount sales amount sales amount sales consumer pharmaceutical medical devices diagnostics total research development expense percent increasedecrease prior year percent segment sales research development activities represent significant part company 's business expenditures relate processes discovering testing developing new products improving existing products well ensuring product efficacy regulatory compliance prior launch company remains committed investing research development aim delivering high quality innovative products worldwide costs research development activities increased compared decrease medical devices diagnostics segment primarily due discontinuation clinical development program nevo sirolimuseluting coronary stent inprocess research development iprd company recorded charge billion included billion impairment iprd related discontinuation phase iii clinical development bapineuzumab iv partial impairment iprd related crucell vaccine business amount billion billion impairment iprd related discontinuation phase iii clinical development bapineuzumab iv billion johnson johnson annual report attributable noncontrolling interest charges relate development projects recently discontinued delayed income expense net income expense net includes royalty income gains losses related sale writedown certain investments equity securities held johnson johnson development corporation gains losses disposal property plant equipment currency gains losses litigation settlements favorable change billion income expense net primarily due lower expenses billion related litigation including product liability billion costs related depuy asr hip program partially offset billion attributed asset writedowns primarily related crucell vaccine business billion higher integrationtransaction currency costs related acquisition synthes inc unfavorable change billion income expense net primarily due net litigation includes product liability billion compared billion net gain litigation additionally compared included higher expenses billion costs related depuy asr hip program adjustment billion value currency option deal costs related acquisition synthes inc included higher gains divestitures businesses billion compared restructuring cordis corporation subsidiary johnson johnson announced discontinuation clinical development program nevo sirolimuseluting coronary stent cessation manufacture marketing cypher cypher select plus sirolimuseluting coronary stents end company recorded pretax charge billion billion included cost products sold restructuring charge see note consolidated financial statements additional details related restructuring interest income expense interest income decreased million compared prior year due lower rates interest earned lower average cash balances cash cash equivalents marketable securities totaled billion end averaged billion compared billion average cash balance decline average cash balance due acquisition synthes inc partially offset cash generated operating activities interest expense decreased million compared due lower average debt balance average debt balance billion versus billion total debt balance end billion compared billion end reduction debt approximately billion primarily due reduction commercial paper interest income decreased million compared prior year due lower rates interest earned despite higher average cash balances cash cash equivalents marketable securities totaled billion end averaged billion compared billion average cash balance increase average cash balance primarily due cash generated operating activities net cash proceeds divestitures interest expense increased million compared due higher average debt balance total debt balance end billion compared billion end higher average debt balance billion versus billion due increased borrowings company increased borrowings capitalizing favorable terms capital markets proceeds borrowings used general corporate purposes segment pretax profit pretax profits segment business follows percent segment sales dollars millions consumer pharmaceutical medical devices diagnostics total less expenses allocated segments earnings provision taxes income see note consolidated financial statements details amounts allocated segments include interest income expense noncontrolling interests general corporate income expense billion billion currency related expense acquisition synthes inc included respectively johnson johnson annual report consumer segment consumer segment pretax profit percent sales versus pretax profit unfavorably impacted billion attributed intangible asset writedowns approximately billion due unfavorable product mix remediation costs associated mcneilppc inc consent decree partially offset cost containment initiatives realized selling marketing administrative expenses addition included higher gains divestitures consumer segment pretax profit decreased primary drivers decline operating profit unfavorable product mix remediation costs associated recall certain otc products partially offset gain divestiture monistat pharmaceutical segment pharmaceutical segment pretax profit percent sales versus pretax profit unfavorably impacted charges billion attributed writedown assets impairment inprocess research development assets related crucell vaccine business discontinuation phase iii clinical development bapineuzumab iv partially offset lower litigation expense billion versus prior year favorable operating expenses billion additionally included gain divestiture bystolicnebivolol ip rights pharmaceutical segment pretax profit decreased primary drivers decrease pretax profit margin higher litigation expenses recorded impact us health care reform fee lower margins integration costs including inventory stepup charge associated crucell acquisition partially offset gains divestitures animal health business ortho dermatologics gain related companys earlier investment crucell lower manufacturing costs medical devices diagnostics segment medical devices diagnostics segment pretax profit percent sales versus medical devices diagnostics segment pretax profit favorably impacted profits synthes sales lower expenses billion litigation including product liability depuy asr hip program billion research development primarily due discontinuation clinical development program nevo sirolimuseluting coronary stent partially offset increase integration costs amortization inventory stepup billion associated acquisition synthes inc billion attributed writedown intangible assets addition included higher gains divestitures versus prior year due divestitures therakos business rhogam additionally included billion restructuring charge related discontinuation clinical development program nevo sirolimuseluting coronary stent medical devices diagnostics segment pretax profit decreased primary drivers decline pretax profit margin medical devices diagnostics segment litigation expenses including product liability costs associated depuy asr hip program restructuring expense costs incurred related acquisition synthes inc increased investment spending provision taxes income worldwide effective income tax rate increase effective tax rate compared due lower tax benefits impairment inprocess research development intangible assets low tax jurisdictions increases taxable income higher tax jurisdictions relative lower tax jurisdictions exclusion benefit us research development rd tax credit cfc lookthrough provisions fiscal year financial results rd tax credit cfc lookthrough provisions enacted law retroactive january entire benefit rd tax credit cfc lookthrough provisions reflected fiscal year financial results tax rate increased compared due certain us expenses fully tax deductible higher us state taxes partially offset increases taxable income lower tax jurisdictions relative higher tax jurisdictions noncontrolling interest charge billion impairment iprd related discontinuation phase iii clinical development bapineuzumab iv recorded billion impairment billion attributable noncontrolling interest liquidity capital resources liquidity cash flows cash cash equivalents billion end compared billion end primary uses cash contributed billion decrease versus prior year approximately billion net cash used investing activities billion net cash used financing activities partially offset billion cash generated operating activities cash flow operations billion result billion net earnings billion noncash charges primarily related depreciation amortization asset writedowns primarily inprocess research development stockbased compensation noncontrolling interest deferred tax provision reduced billion related changes assets liabilities net effects acquisitions investing activities use billion primarily billion additions property plant equipment andacquisitions net cash acquired billion partially offset net sales investments marketable securities johnson johnson annual report billion billion proceeds disposal assets financing activities use billion repurchase common stock billion primarily acquisition synthes inc dividends shareholders billion net retirement short longterm debt billion partially offset billion net proceeds stock options exercisedexcess tax benefits company continued access liquidity commercial paper market additional details borrowings see note consolidated financial statements company anticipates operating cash flows existing credit facilities access commercial paper markets provide sufficient resources fund operating needs concentration credit risk global concentration credit risk respect trade accounts receivables continues limited due large number customers globally adherence internal credit policies credit limits recent economic challenges italy spain greece portugal southern european region impacted certain payment patterns historically longer experienced us international markets total net trade accounts receivable balance southern european region approximately billion december approximately billion january approximately billion december approximately billion january southern european region net trade accounts receivable balance related company 's consumer vision care diabetes care businesses well certain pharmaceutical medical devices diagnostics customers line historical collection patterns remaining balance net trade accounts receivable southern european region negatively impacted timing payments certain government owned supported health care customers well certain distributors pharmaceutical medical devices diagnostics local affiliates total net trade accounts receivable balance customers approximately billion december billion january company continues receive payments customers cases late payment premiums customers payment expected periods time longer one year revenue trade receivables discounted estimated period time collection allowances doubtful accounts increased customers immaterial date company continue work closely customers payment plans monitor economic situation take appropriate actions necessary financing market risk company uses financial instruments manage impact foreign exchange rate changes cash flows accordingly company enters forward foreign exchange contracts protect value certain foreign currency assets liabilities hedge future foreign currency transactions primarily related product costs gains losses contracts offset gains losses underlying transactions appreciation us dollar december market rates would increase unrealized value companys forward contracts million conversely depreciation us dollar december market rates would decrease unrealized value companys forward contracts million either scenario gain loss forward contract would offset gain loss underlying transaction therefore would impact future anticipated earnings cash flows company hedges exposure fluctuations currency exchange rates effect certain assets liabilities foreign currency entering currency swap contracts change spread us foreign interest rates companys interest rate sensitive financial instruments would either increase decrease unrealized value companys swap contracts approximately million either scenario maturity gain loss swap contract would offset gain loss underlying transaction therefore would impact future anticipated cash flows company enter financial instruments trading speculative purposes company policy entering contracts parties least equivalent credit rating counterparties contracts major financial institutions significant concentration exposure one counterparty management believes risk loss remote company access substantial sources funds numerous banks worldwide september company secured new day credit facility total credit available company approximates billion expires september interest charged borrowings credit line agreement based either bids provided banks prime rate london interbank offered rates libor plus applicable margins commitment fees agreement material total borrowings end billion billion respectively reduction debt approximately billion primarily due reduction commercial paper net cash cash current marketable securities net debt billion compared net cash billion total debt represented total capital shareholders equity total debt total capital shareholders equity per share end compared yearend johnson johnson annual report increase summary borrowings found note consolidated financial statements contractual obligations commitments companys contractual obligations primarily leases debt unfunded retirement plans significant obligations satisfy obligations company use cash operations following table summarizes companys contractual obligations aggregate maturities december see notes consolidated financial statements details longterm interest unfunded dollars millions debt obligations debt obligations retirement plans operating leases total total tax matters see note consolidated financial statements share repurchase dividends july company announced board directors approved stock repurchase program authorizing company buy back billion companys common stock january company repurchased aggregate million shares johnson johnson common stock cost billion stock repurchase program completed company funded share repurchase program combination available cash debt pursuant accelerated stock repurchase agreements connection acquisition synthes inc company made purchases common stock open market fiscal third fourth quarters company increased dividend th consecutive year cash dividends paid per share compared dividends per share per share dividends distributed follows first quarter second quarter third quarter fourth quarter total january board directors declared regular quarterly cash dividend per share payable march shareholders record february company expects continue practice paying regular cash dividends information critical accounting policies estimates managements discussion analysis results operations financial condition based companys consolidated financial statements prepared accordance accounting principles generally accepted us gaap preparation financial statements requires management make estimates assumptions affect amounts reported revenues expenses assets liabilities related disclosures actual results may may differ estimates company believes understanding certain key accounting policies estimates essential achieving insight companys operating results financial condition key accounting policies include revenue recognition income taxes legal selfinsurance contingencies valuation longlived assets assumptions used determine amounts recorded pensions employee benefit plans accounting stock johnson johnson annual report options revenue recognition company recognizes revenue product sales goods shipped delivered title risk loss pass customer provisions certain rebates sales incentives trade promotions coupons product returns discounts customers accounted reductions sales period related sales recorded product discounts granted based terms arrangements direct indirect market participants well market conditions including prices charged competitors rebates largest medicaid rebate provision estimated based contractual terms historical experience trend analysis projected market conditions various markets served company evaluates market conditions products groups products primarily analysis wholesaler thirdparty sellthrough market research data well internally generated information sales returns generally estimated recorded based historical sales returns information products exhibit unusual sales return patterns due dating competition marketing matters specifically investigated analyzed part accounting sales return accruals sales returns allowances represent reserve products may returned due expiration destruction field specific areas product recall returns reserve based historical return trends product market percent gross sales accordance companys accounting policies company generally issues credit customers returned goods companys sales returns reserves accounted accordance us gaap guidance revenue recognition right return exists sales returns reserves recorded full sales value sales returns consumer pharmaceutical segments almost exclusively resalable sales returns certain franchises medical devices diagnostics segment typically resalable material company rarely exchanges products inventory returned products sales returns reserve total company ranged annual net trade sales fiscal reporting years promotional programs product listing allowances cooperative advertising arrangements recorded year incurred continuing promotional programs include coupons volumebased sales incentive programs redemption cost consumer coupons based historical redemption experience product value volumebased incentive programs based estimated sales volumes incentive period recorded products sold company also earns service revenue copromotion certain products years presented service revenues less total revenues included sales customers arrangements evaluated determine appropriate amounts deferred addition company enters collaboration arrangements contain multiple revenue generating activities amounts due collaborative partners arrangements recognized activity performed delivered based relative fair value upfront fees received part arrangements deferred recognized performance period see note consolidated financial statements additional disclosures collaborations reasonably likely changes assumptions used calculate accruals rebates returns promotions anticipated material effect financial statements company currently discloses impact changes assumptions quarterly annual filing material financial statement impact tables show progression accrued rebates returns promotions reserve doubtful accounts reserve cash discounts segment business fiscal years ended december january johnson johnson annual report consumer segment balance balance dollars millions beginning period accruals paymentscredits end period accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total includes reserve customer rebates million december million january recorded contra asset pharmaceutical segment balance balance dollars millions beginning period accruals paymentscredits end period accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total includes reserve customer rebates million december million january recorded contra asset johnson johnson annual report medical devices diagnostics segment balance balance dollars millions beginning period accruals paymentscredits end period accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total includes reserve customer rebates million december million january recorded contra asset income taxes income taxes recorded based amounts refundable payable current year include results difference us gaap accounting tax reporting recorded deferred tax assets liabilities company estimates deferred tax assets liabilities based current tax regulations rates changes tax laws rates may affect recorded deferred tax assets liabilities future company unrecognized tax benefits uncertain tax positions company follows us gaap prescribes recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return management believes changes estimates would material effect company 's results operations cash flows financial position december january cumulative amounts undistributed international earnings approximately billion billion respectively december january company 's foreign subsidiaries held balances cash cash equivalents amounts billion billion respectively company provided deferred taxes undistributed earnings certain international subsidiaries earnings considered permanently reinvested company intends continue reinvest earnings international operations company decided later date repatriate earnings us company would required provide net tax effects amounts company determine deferred tax liability associated undistributed earnings determination practical see note consolidated financial statements information regarding income taxes legal self insurance contingencies company records accruals various contingencies including legal proceedings product liability claims arise normal course business accruals based managements judgment probability losses applicable actuarially determined estimates company self insurance whollyowned captive insurance company insured certain limits addition accruals self insurance program claims exceed insurance coverage accrued losses probable amounts reasonably estimated additionally company records insurance receivable amounts thirdparty insurers recovery probable appropriate reserves receivables recorded estimated amounts may collected thirdparty insurers company follows provisions us gaap recording litigation related contingencies liability recorded loss probable reasonably estimated best estimate loss within range accrued however estimate range better minimum amount accrued johnson johnson annual report longlived intangible assets company assesses changes economic conditions makes assumptions regarding estimated future cash flows evaluating value companys property plant equipment goodwill intangible assets assumptions estimates may change time may may necessary company record impairment charges employee benefit plans company sponsors various retirement pension plans including defined benefit defined contribution termination indemnity plans cover employees worldwide plans based assumptions discount rate expected return plan assets expected salary increases health care cost trend rates see note consolidated financial statements details rates effect rate change would companys results operations stock based compensation company recognizes compensation expense associated issuance equity instruments employees services fair value award estimated date grant using blackscholes option valuation model expensed financial statements vesting period input assumptions used determining fair value expected life expected volatility riskfree rate dividend yield see note consolidated financial statements additional information new accounting pronouncements refer note consolidated financial statements recently adopted accounting pronouncements recently issued accounting pronouncements yet adopted december economic market factors company aware products used environment decade policymakers consumers businesses expressed concerns rising cost health care response concerns company longstanding policy pricing products responsibly period united states weighted average compound annual growth rate companys net price increases health care products prescription overthecounter drugs hospital professional products us consumer price index cpi inflation rates continue effect worldwide economies consequently way companies operate company accounted operations venezuela highly inflationary prior threeyear cumulative inflation rate surpassed face increasing costs company strives maintain profit margins cost reduction programs productivity improvements periodic price increases february venezuelan government announced devaluation currency effect devaluation expected material impact company 's full year results company exposed fluctuations currency exchange rates change value us dollar compared foreign currencies company sales income expense would increased decreased translation foreign sales approximately million income million company faces various worldwide health care changes may continue result pricing pressures include health care cost containment government legislation relating sales promotions reimbursement health care products changes behavior spending patterns purchasers health care products services including delaying medical procedures rationing prescription medications reducing frequency physician visits foregoing health care insurance coverage result current global economic downturn may continue impact companys businesses company also operates environment become increasingly hostile intellectual property rights generic drug firms filed abbreviated new drug applications andas seeking market generic forms companys key pharmaceutical products prior expiration applicable patents covering products event company successful defending patent claims challenged anda filings generic firms introduce generic versions product issue resulting potential substantial market share revenue losses product information see discussion litigation filers abbreviated new drug applications note consolidated financial statements legal proceedings johnson johnson certain subsidiaries involved various lawsuits claims regarding product liability intellectual property commercial matters governmental investigations legal proceedings arise time time ordinary course business company records accruals contingencies probable liability incurred amount loss reasonably estimated company accrued certain litigation matters continues monitor related legal issue adjust accruals new information developments accordance accounting standards codification asc litigation regulatory matters currently disclosed loss probable reasonably possible company unable determine estimate possible loss range loss beyond amounts already accrued matters affected various factors including whether damages sought johnson johnson annual report proceedings unsubstantiated indeterminate scientific legal discovery commenced complete proceedings early stages matters present legal uncertainties significant facts dispute numerous parties involved company 's opinion based examination matters experience date discussions counsel ultimate outcome legal proceedings net liabilities accrued company 's balance sheet expected material adverse effect company 's financial position however resolution reporting period one matters either alone aggregate may material adverse effect company 's results operations cash flows period see note consolidated financial statements information regarding legal proceedings common stock market prices companys common stock listed new york stock exchange symbol jnj february record holders common stock company composite market price ranges johnson johnson common stock high low high low first quarter second quarter third quarter fourth quarter yearend close johnson johnson annual report cautionary factors may affect future results annual report contains forwardlooking statements forwardlooking statements relate strictly historical current facts anticipate results based managements plans subject uncertainty forwardlooking statements may identified use words plans expects anticipates estimates words similar meaning conjunction among things discussions future operations financial performance companys strategy growth product development regulatory approval market position expenditures forwardlooking statements based current expectations future events company guarantee forwardlooking statement accurate although company believes reasonable expectations assumptions investors realize underlying assumptions prove inaccurate unknown risks uncertainties materialize actual results could vary materially companys expectations projections investors therefore cautioned place undue reliance forwardlooking statements company undertake update forwardlooking statements result new information future events developments risks uncertainties include limited general industry conditions competition economic factors interest rate currency exchange rate fluctuations technological advances new products patents attained competitors challenges inherent new product development including obtaining regulatory approvals challenges patents significant litigation government action adverse company impact business combinations financial distress bankruptcies experienced significant customers suppliers changes governmental laws regulations us foreign health care reforms trends toward health care cost containment increased scrutiny health care industry government agencies changes behavior spending patterns purchasers health care products services financial instability international economies sovereign risk disruptions due natural disasters manufacturing difficulties delays complex global supply chains increasing regulatory requirements product efficacy safety concerns resulting product recalls regulatory action companys report year ended december includes exhibit discussion additional factors could cause actual results differ expectations company notes factors permitted private securities litigation reform act johnson johnson annual report johnson johnson subsidiaries consolidated balance sheets december january dollars millions except share per share amounts note assets current assets cash cash equivalents notes marketable securities notes accounts receivable trade less allowances doubtful accounts inventories notes deferred taxes income note prepaid expenses receivables total current assets property plant equipment net notes intangible assets net notes goodwill notes deferred taxes income note assets total assets liabilities shareholders equity current liabilities loans notes payable note accounts payable accrued liabilities accrued rebates returns promotions accrued compensation employee related obligations accrued taxes income total current liabilities longterm debt note deferred taxes income note employee related obligations notes liabilities total liabilities shareholders equity preferred stock without par value authorized unissued shares common stock par value per share note authorized shares issued shares accumulated comprehensive income note retained earnings less common stock held treasury cost note shares shares total shareholders equity total liabilities shareholders equity see notes consolidated financial statements johnson johnson annual report johnson johnson subsidiaries consolidated statements earnings dollars shares millions except per share amounts note sales customers cost products sold gross profit selling marketing administrative expenses research development expense inprocess research development note interest income interest expense net portion capitalized note income expense net restructuring note earnings provision taxes income provision taxes income note net earnings add net loss attributable noncontrolling interest net earnings attributable johnson johnson net earnings per share attributable johnson johnson notes basic diluted cash dividends per share average shares outstanding notes basic diluted see notes consolidated financial statements johnson johnson annual report johnson johnson subsidiaries consolidated statements comprehensive income dollars millions note net earnings comprehensive income loss net tax foreign currency translation securities unrealized holding gain loss arising period reclassifications earnings net change employee benefit plans prior service cost amortization period prior service cost current year gain loss amortization period gain loss current year effect exchange rates net change derivatives hedges unrealized gain loss arising period reclassifications earnings net change comprehensive income loss comprehensive income comprehensive loss attributable noncontrolling interest net tax comprehensive income attributable johnson johnson tax effects comprehensive income fiscal years ended respectively securities million million million employee benefit plans million million million derivatives hedges million million million foreign currency translation adjusted income taxes relates permanent investments international subsidiaries see notes consolidated financial statements johnson johnson annual report johnson johnson subsidiaries consolidated statements equity dollars millions note accumulated treasury retained comprehensive common stock stock total earnings income issued amount amount balance january net earnings attributable johnson johnson cash dividends paid employee compensation stock option plans repurchase common stock comprehensive income net tax balance january net earnings attributable johnson johnson cash dividends paid employee compensation stock option plans repurchase common stock comprehensive income net tax balance january net earnings attributable johnson johnson cash dividends paid employee compensation stock option plans issuance common stock associated acquisition synthes inc repurchase common stock comprehensive income net tax balance december includes repurchase common stock associated acquisition synthes inc see notes consolidated financial statements johnson johnson annual report johnson johnson subsidiaries consolidated statements cash flows dollars millions note cash flows operating activities net earnings adjustments reconcile net earnings cash flows operating activities depreciation amortization property intangibles stock based compensation noncontrolling interest asset writedowns impairments deferred tax provision accounts receivable allowances changes assets liabilities net effects acquisitions increase accounts receivable increase inventories increase accounts payable accrued liabilities increase current noncurrent assets decreaseincrease current noncurrent liabilities net cash flows operating activities cash flows investing activities additions property plant equipment proceeds disposal assets acquisitions net cash acquired note purchases investments sales investments primarily intangibles net cash used investing activities cash flows financing activities dividends shareholders repurchase common stock proceeds shortterm debt retirement shortterm debt proceeds longterm debt retirement longterm debt proceeds exercise stock optionsexcess tax benefits net cash used financing activities effect exchange rate changes cash cash equivalents decreaseincrease cash cash equivalents cash cash equivalents beginning year note cash cash equivalents end year note supplemental cash flow data cash paid year interest income taxes supplemental schedule noncash investing financing activities issuance common stock associated acquisition synthes inc treasury stock issued employee compensation stock option plans net cash proceeds conversion debt johnson johnson annual report acquisitions fair value assets acquired fair value liabilities assumed noncontrolling interests net fair value acquisitions less issuance common stock associated acquisition synthes inc net cash paid acquisitions see notes consolidated financial statements johnson johnson annual report notes consolidated financial statements summary significant accounting policies principles consolidation consolidated financial statements include accounts johnson johnson subsidiaries company intercompany accounts transactions eliminated description company business segments company approximately employees worldwide engaged research development manufacture sale broad range products health care field company conducts business virtually countries world primary focus products related human health wellbeing company organized three business segments consumer pharmaceutical medical devices diagnostics consumer segment includes broad range products used baby care skin care oral care wound care womens health fields well nutritional overthecounter pharmaceutical products wellness prevention platforms products marketed general public sold retail outlets distributors throughout world pharmaceutical segment includes products following areas antiinfective antipsychotic contraceptive gastrointestinal hematology immunology infectious diseases neurology oncology pain management thrombosis vaccines products distributed directly retailers wholesalers health care professionals prescription use medical devices diagnostics segment includes broad range products distributed wholesalers hospitals retailers used principally professional fields physicians nurses hospitals clinics include products treat cardiovascular disease orthopaedic neurological products blood glucose monitoring insulin delivery products general surgery biosurgical energy products professional diagnostic products infection prevention products disposable contact lenses new accounting pronouncements recently adopted accounting pronouncements fiscal first quarter company adopted financial accounting standards board fasb guidance amendments issued related goodwill impairment testing amendments update entity option first assess qualitative factors determine whether existence events circumstances leads determination likely fair value reporting unit less carrying amount assessing totality events circumstances entity determines likely fair value reporting unit less carrying amount performing twostep impairment test unnecessary however entity concludes otherwise required perform first step twostep impairment test update became effective annual interim goodwill impairment tests performed fiscal years beginning december adoption standard material impact companys results operations cash flows financial position fiscal first quarter company adopted fasb amendment disclosure requirements presentation comprehensive income amendment requires nonowner changes stockholders equity presented either single continuous statement comprehensive income two separate consecutive statements guidance became effective retrospectively interim periods annual periods beginning december fiscal first quarter company adopted fasb amendments disclosure requirements fair value measurement amendments result convergence fair value measurement disclosure requirements us generally accepted accounting principles gaap international financial reporting standards ifrs guidance became effective prospectively interim periods annual periods beginning december adoption standard material impact companys results operations cash flows financial position recently issued accounting standards adopted december fiscal third quarter fasb issued guidance amendments related testing indefinite lived intangible assets impairment amendments update entity option first assess qualitative factors determine whether existence events circumstances indicates likely indefinitelived intangible asset impaired assessing totality events circumstances entity concludes likely indefinitelived intangible asset impaired entity required determine fair value however entity concludes otherwise required determine fair value indefinitelived intangible asset perform quantitative impairment test entity also option bypass qualitative assessment indefinitelived intangible asset period proceed directly performing quantitative impairment test update became effective annual interim impairment tests performed fiscal years beginning september johnson johnson annual report however early adoption permitted adoption standard expected material impact companys results operations cash flows financial position february fasb issued guidance related additional reporting disclosure amounts reclassified accumulated comprehensive income oci new guidance companies required disclose amount income loss reclassified oci respective line item income statement net income presented guidance allows companies elect whether disclose reclassification either notes financial statements face income statement update effective annual interim reporting periods fiscal years beginning december adoption standard expected material impact companys results operations cash flows financial position cash equivalents company considers securities maturities three months less purchased cash equivalents investments shortterm marketable securities carried cost approximates fair value investments classified availableforsale carried estimated fair value unrealized gains losses recorded component accumulated comprehensive income longterm debt securities company ability intent hold maturity carried amortized cost management determines appropriate classification investment debt equity securities time purchase reevaluates determination balance sheet date company periodically reviews investments equity securities impairment adjusts investments fair value decline market value deemed temporary losses securities considered temporary loss recognized earnings property plant equipment depreciation property plant equipment stated cost company utilizes straightline method depreciation estimated useful lives assets building building equipment years land leasehold improvements years machinery equipment years company capitalizes certain computer software development costs included machinery equipment incurred connection developing obtaining computer software internal use capitalized software costs amortized estimated useful lives software generally range years company reviews longlived assets assess recoverability using undiscounted cash flows certain events changes operating economic conditions occur impairment assessment may performed recoverability carrying value assets asset determined impaired loss measured based difference assets fair value carrying value quoted market prices available company estimate fair value using discounted value estimated future cash flows revenue recognition company recognizes revenue product sales goods shipped delivered title risk loss pass customer provisions certain rebates sales incentives trade promotions coupons product returns discounts customers accounted reductions sales period related sales recorded product discounts granted based terms arrangements direct indirect market participants well market conditions including prices charged competitors rebates largest medicaid rebate provision estimated based contractual terms historical experience trend analysis projected market conditions various markets served company evaluates market conditions products groups products primarily analysis wholesaler thirdparty sellthrough market research data well internally generated information sales returns generally estimated recorded based historical sales returns information products exhibit unusual sales return patterns due dating competition marketing matters specifically investigated analyzed part accounting sales returns accruals sales returns allowances represent reserve products may returned due expiration destruction field specific areas product recall returns reserve based historical return trends product market percent gross sales accordance companys accounting policies company generally issues credit customers returned goods companys sales returns reserves accounted accordance us gaap guidance revenue recognition right return exists sales returns reserves recorded full sales value sales returns consumer pharmaceutical segments almost exclusively resalable sales returns certain franchises medical devices diagnostics segment typically resalable material company rarely exchanges products inventory johnson johnson annual report returned products sales returns reserve total company ranged annual sales customers fiscal reporting years promotional programs product listing allowances cooperative advertising arrangements recorded year incurred continuing promotional programs include coupons volumebased sales incentive programs redemption cost consumer coupons based historical redemption experience product value volumebased incentive programs based estimated sales volumes incentive period recorded products sold company also earns service revenue copromotion certain products includes sales customers arrangements evaluated determine appropriate amounts deferred shipping handling shipping handling costs incurred million million million respectively included selling marketing administrative expense amount revenue received shipping handling less sales customers periods presented inventories inventories stated lower cost market determined firstin firstout method intangible assets goodwill authoritative literature us gaap requires goodwill intangible assets indefinite lives assessed annually impairment company completed annual impairment test fiscal fourth quarter future impairment tests performed annually fiscal fourth quarter sooner warranted case certain indefinite lived intangible assets fiscal second third quarters purchased inprocess research development accounted indefinite lived intangible asset underlying project completed point intangible asset accounted definite lived intangible asset abandoned point intangible asset written partially impaired intangible assets finite useful lives continue amortized useful lives reviewed impairment warranted economic conditions see note details intangible assets goodwill financial instruments required us gaap derivative instruments recorded balance sheet fair value fair value exit price would received sell asset paid transfer liability fair value marketbased measurement determined using assumptions market participants would use pricing asset liability authoritative literature establishes threelevel hierarchy prioritize inputs used measuring fair value level highest priority level lowest changes fair value derivatives recorded period current earnings comprehensive income depending whether derivative designated part hedge transaction type hedge transaction company documents relationships hedged items derivatives overall risk management strategy includes reasons undertaking hedge transactions entering derivatives objectives strategy minimize foreign currency exposures impact companys financial performance protect companys cash flow adverse movements foreign exchange rates ensure appropriateness financial instruments manage enterprise risk associated financial institutions see note additional information financial instruments product liability accruals product liability claims recorded undiscounted basis probable liability incurred amount liability reasonably estimated based existing information accruals adjusted periodically additional information becomes available result cost availability factors effective november company ceased purchasing thirdparty product liability insurance company self insurance whollyowned captive insurance company insured certain limits addition accruals self insurance program claims exceed insurance coverage accrued losses probable amounts reasonably estimated based availability prior coverage receivables insurance recoveries related product liability claims recorded undiscounted basis probable recovery realized appropriate reserves receivables recorded estimated amounts may collected thirdparty insurers concentration credit risk global concentration credit risk respect trade accounts receivables continues limited due large number customers globally adherence internal credit policies credit limits recent economic challenges italy spain greece portugal southern european region impacted certain payment patterns historically longer experienced us international markets total net trade accounts receivable balance johnson johnson annual report southern european region approximately billion december approximately billion january approximately billion december approximately billion january southern european region net trade accounts receivable balance related company 's consumer vision care diabetes care businesses well certain pharmaceutical medical devices diagnostics customers line historical collection patterns remaining balance net trade accounts receivable southern european region negatively impacted timing payments certain government owned supported health care customers well certain distributors pharmaceutical medical devices diagnostics local affiliates total net trade accounts receivable balance customers approximately billion december billion january company continues receive payments customers cases late payment premiums customers payment expected periods time longer one year revenue trade receivables discounted estimated period time collection allowances doubtful accounts increased customers immaterial date company continue work closely customers payment plans monitor economic situation take appropriate actions necessary research development research development expenses expensed incurred upfront milestone payments made third parties connection research development collaborations expensed incurred point regulatory approval payments made third parties subsequent regulatory approval capitalized amortized remaining useful life related product amounts capitalized payments included intangibles net accumulated amortization company enters collaborative arrangements typically pharmaceutical biotechnology companies develop commercialize drug candidates intellectual property arrangements typically involve two parties active participants collaboration exposed significant risks rewards dependent commercial success activities collaborations usually involve various activities one parties including research development marketing selling distribution often collaborations require upfront milestone royalty profit share payments contingent upon occurrence certain future events linked success asset development amounts due collaborative partners related development activities generally reflected reduction research development expense performance contract development services central companys operations general income statement presentation collaborations follows naturetype collaboration statement earnings presentation thirdparty sale product sales customers royaltiesmilestones paid collaborative partner postregulatory approval cost goods sold royalties received collaborative partner income expense net upfront payments milestones paid collaborative partner preregulatory research development expense approval research development payments collaborative partner research development expense research development payments received collaborative partner reduction research development expense milestones capitalized intangible assets amortized cost goods sold useful life years presented individual project represented greater total annual consolidated research development expense advertising costs associated advertising expensed year incurred included selling marketing administrative expenses advertising expenses worldwide comprised television radio print media internet advertising billion billion billion respectively income taxes income taxes recorded based amounts refundable payable current year include results difference us gaap accounting tax reporting recorded deferred tax assets liabilities company estimates deferred tax assets liabilities based current tax regulations rates changes tax laws rates may affect recorded deferred tax assets liabilities future johnson johnson annual report company unrecognized tax benefits uncertain tax positions company follows us gaap prescribes recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return management believes changes estimates would material effect company 's results operations cash flows financial position december january cumulative amounts undistributed international earnings approximately billion billion respectively december january company 's foreign subsidiaries held balances cash cash equivalents amounts billion billion respectively company provided deferred taxes undistributed earnings certain international subsidiaries earnings considered permanently reinvested company intends continue reinvest earnings international operations company decided later date repatriate earnings us company would required provide net tax effects amounts company determine deferred tax liability associated undistributed earnings determination practicable see note consolidated financial statements information regarding income taxes net earnings per share basic earnings per share computed dividing net earnings available common shareholders weighted average number common shares outstanding period diluted earnings per share reflects potential dilution could occur securities exercised converted common stock using treasury stock method use estimates preparation consolidated financial statements conformity accounting principles generally accepted us requires management make estimates assumptions affect amounts reported estimates used accounting sales discounts rebates allowances incentives product liabilities income taxes depreciation amortization employee benefits contingencies intangible asset liability valuations actual results may may differ estimates company follows provisions us gaap recording litigation related contingencies liability recorded loss probable reasonably estimated best estimate loss within range accrued however estimate range better minimum amount accrued annual closing date company follows concept fiscal year ends sunday nearest end month december normally fiscal year consists weeks every five six years fiscal year consists weeks case case reclassification certain prior period amounts reclassified conform current year presentation cash cash equivalents current marketable securities end cash cash equivalents current marketable securities comprised dollars millions cash government securities obligations corporate debt securities money market funds time deposits total cash cash equivalents current marketable securities estimated fair value amortized cost december estimated fair value million january reflecting million unrealized gain government securities obligations december current marketable securities consisted million million government securities obligations corporate debt securities respectively january current marketable securities consisted million million government securities obligations corporate debt securities respectively fair value government securities obligations corporate debt securities estimated using quoted broker prices significant observable inputs company invests excess cash deposits major banks throughout world highquality money market instruments company policy making investments commercial institutions least johnson johnson annual report equivalent credit rating inventories end inventories comprised dollars millions raw materials supplies goods process finished goods total inventories december remaining inventory stepup related synthes inc acquisition approximately million property plant equipment end property plant equipment cost accumulated depreciation dollars millions land land improvements buildings building equipment machinery equipment construction progress total property plant equipment gross less accumulated depreciation total property plant equipment net company capitalizes interest expense part cost construction facilities equipment interest expense capitalized million million million respectively depreciation expense including amortization capitalized interest billion billion billion respectively upon retirement disposal property plant equipment costs related amounts accumulated depreciation amortization eliminated asset accumulated depreciation accounts respectively difference net asset value proceeds recorded earnings intangible assets goodwill end gross net amounts intangible assets dollars millions intangible assets definite lives patents trademarks gross less accumulated amortization patents trademarks net customer relationships intangibles gross less accumulated amortization customer relationships intangibles net intangible assets indefinite lives trademarks purchased inprocess research development total intangible assets indefinite lives total intangible assets net goodwill december january allocated segment business follows johnson johnson annual report med devices dollars millions consumer pharmaceuticals diagnostics total goodwill january acquisitions currency translationother goodwill january acquisitions currency translationother goodwill december weighted average amortization periods patents trademarks customer relationships intangible assets years years respectively amortization expense amortizable assets million million million tax fiscal years ended december january january respectively estimated amortization expense five succeeding years approximates million tax per year amortization expense included cost products sold intangible assets goodwill increased billion billion respectively based purchase price allocation synthes inc acquisition see note consolidated financial statements additional details synthes inc acquisition increase intangible assets partially offset billion intangible asset writedowns billion impairment purchased inprocess research development primarily related discontinuation phase iii clinical development bapineuzumab iv partial impairment related crucell vaccine business fair value measurements company uses forward exchange contracts manage exposure variability cash flows primarily related foreign exchange rate changes future intercompany product thirdparty purchases raw materials denominated foreign currency company also uses cross currency interest rate swaps manage currency risk primarily related borrowings types derivatives designated cash flow hedges company also uses forward exchange contracts manage exposure variability cash flows repatriation foreign dividends contracts designated net investment hedges additionally company uses forward exchange contracts offset exposure certain foreign currency assets liabilities forward exchange contracts designated hedges therefore changes fair values derivatives recognized earnings thereby offsetting current earnings effect related foreign currency assets liabilities company enter derivative financial instruments trading speculative purposes contain credit risk related contingent features requirements post collateral ongoing basis company monitors counterparty credit ratings company considers credit nonperformance risk low company enters agreements commercial institutions least equivalent credit rating december company notional amounts outstanding forward foreign exchange contracts cross currency interest rate swaps billion billion respectively derivative instruments recorded balance sheet fair value changes fair value derivatives recorded period current earnings comprehensive income depending whether derivative designated part hedge transaction type hedge transaction designation cash flow hedge made entrance date derivative contract inception derivatives expected highly effective changes fair value derivative designated cash flow hedge highly effective recorded accumulated comprehensive income underlying transaction affects earnings reclassified earnings account hedged transaction gainslosses net investment hedges accounted currency translation account insignificant ongoing basis company assesses whether derivative continues highly effective offsetting changes cash flows hedged items derivative longer expected highly effective hedge accounting discontinued hedge ineffectiveness included current period earnings income expense net december balance deferred net gains derivatives included accumulated comprehensive income million aftertax additional information see consolidated statements comprehensive income note company expects substantially amount related foreign exchange contracts reclassified earnings next months result transactions expected occur period maximum length time company hedging transaction exposure months excluding interest rate swaps amount ultimately realized earnings differ foreign exchange rates change realized gains losses ultimately determined actual exchange rates maturity derivative following table summary activity related designated derivatives fiscal years ended december johnson johnson annual report january gainloss gainloss reclassified gainloss recognized dollars millions recognized accumulated oci accumulated oci income incomeexpense cash flow hedges income statement caption sales customers cost products sold research development expense interest incomeinterest expense net income expense net total amounts shown table net tax effective portion ineffective portion foreign exchange contracts cross currency interest rate swaps fiscal years ended december january gain million loss million respectively recognized income expense net relating foreign exchange contracts designated hedging instruments fair value exit price would received sell asset paid transfer liability fair value marketbased measurement determined using assumptions market participants would use pricing asset liability authoritative literature establishes threelevel hierarchy prioritize inputs used measuring fair value levels within hierarchy described level highest priority level lowest fair value derivative financial instrument ie forward exchange contract currency swap aggregation currency future cash flows discounted present value prevailing market interest rates subsequently converted us dollar current spot foreign exchange rate company believe fair values derivative instruments materially differ amounts could realized upon settlement maturity changes fair value material effect companys results operations cash flows financial position company also holds equity investments classified level traded active exchange market company significant financial assets liabilities would require revised valuations standard recognized fair value following three levels inputs used measure fair value level quoted prices active markets identical assets liabilities level significant observable inputs level significant unobservable inputs johnson johnson annual report companys significant financial assets liabilities measured fair value december january follows dollars millions level level level total total derivatives designated hedging instruments assets foreign exchange contracts cross currency interest rate swaps total liabilities foreign exchange contracts cross currency interest rate swaps total derivatives designated hedging instruments assets foreign exchange contracts swiss franc option total liabilities foreign exchange contracts investments assets liabilities classified level exception investments million classified level includes million million noncurrent assets fiscal years ending december january respectively includes million million noncurrent liabilities fiscal years ending december january respectively cross currency interest rate swaps related outstanding eur gbp notes matured november swaps settled fair market value replaced new swaps currency option related acquisition synthes inc expired january classified noncurrent assets see notes financial assets liabilities held carrying amount consolidated balance sheet johnson johnson annual report borrowings components longterm debt follows dollars millions effective rate effective rate debentures due notes due debentures due month libor frn due month libor frn due notes due notes due debentures due debentures due notes due b euro b euro zero coupon convertible subordinated debentures due debentures due notes due debentures due notes due mm gbp mm gbp notes due debentures due notes due debentures due debentures due notes due less current portion weighted average effective rate translation rate december translation rate january excess fair value carrying value debt billion billion fair value noncurrent debt estimated using market prices corroborated quoted broker prices significant observable inputs company access substantial sources funds numerous banks worldwide september company secured new day credit facility total credit available company approximates billion expires september interest charged borrowings credit line agreements based either bids provided banks prime rate london interbank offered rates libor plus applicable margins commitment fees agreements material throughout company continued access liquidity commercial paper market shortterm borrowings current portion longterm debt amounted approximately billion end billion borrowed commercial paper program remainder principally represents local borrowing international subsidiaries company shelf registration us securities exchange commission enables company issue debt securities warrants purchase debt securities timely basis johnson johnson annual report aggregate maturities longterm obligations commencing dollars millions income taxes provision taxes income consists dollars millions currently payable us taxes international taxes total currently payable deferred us taxes international taxes total deferred provision taxes income comparison income tax expense us statutory rate companys effective tax rate follows dollars millions us international earnings taxes income tax rates us statutory rate international operations excluding ireland ireland puerto rico operations research orphan drug tax credits us state local us manufacturing deduction us tax international income effective tax rate includes us expenses fully tax deductible primarily related litigation expense increase effective tax rate compared due lower tax benefits impairment inprocess research development intangible assets low tax jurisdictions increases taxable income higher tax jurisdictions relative lower tax jurisdictions exclusion benefit us research development rd tax credit cfc lookthrough provisions fiscal year financial results rd tax credit cfc lookthrough provisions enacted law retroactive january entire benefit rd tax credit cfc lookthrough provisions reflected fiscal year financial results increase tax rate compared primarily due certain us expenses fully tax deductible higher us state taxes partially offset increases taxable income lower tax jurisdictions relative higher tax jurisdictions johnson johnson annual report temporary differences carryforwards follows deferred tax deferred tax dollars millions asset liability asset liability employee related obligations stock based compensation depreciation nondeductible intangibles international rd capitalized tax reserves liabilities income reported tax purposes net operating loss carryforward international miscellaneous international miscellaneous us total deferred income taxes difference net deferred tax income per balance sheet net deferred tax included taxes income balance sheet company whollyowned international subsidiaries cumulative net losses company believes likely subsidiaries realize future taxable income sufficient utilize deferred tax assets following table summarizes activity related unrecognized tax benefits dollars millions beginning year increases related current year tax positions increases related prior period tax positions decreases related prior period tax positions settlements lapse statute limitations end year unrecognized tax benefits billion december recognized would affect companys annual effective tax rate company conducts business files tax returns numerous countries currently tax audits progress number tax authorities us internal revenue service irs completed audit tax years however limited number issues remaining open prior tax years going back major jurisdictions company conducts business years remain open generally back year company believes possible audits may completed tax authorities jurisdictions next twelve months however company able provide reasonably reliable estimate timing future tax payments relating uncertain tax positions company classifies liabilities unrecognized tax benefits related interest penalties longterm liabilities interest expense penalties related unrecognized tax benefits classified income tax expense company recognized tax interest million expense million expense million income respectively total amount accrued interest million million respectively johnson johnson annual report employee related obligations end employee related obligations recorded consolidated balance sheets dollars millions pension benefits postretirement benefits postemployment benefits deferred compensation total employee obligations less current benefits payable employee related obligations noncurrent prepaid employee related obligations million million respectively included assets consolidated balance sheets pensions benefit plans company sponsors various retirement pension plans including defined benefit defined contribution termination indemnity plans cover employees worldwide company also provides postretirement benefits primarily health care eligible us retired employees dependents many international employees covered governmentsponsored programs cost company significant retirement plan benefits primarily based employees compensation last three five years retirement number years service international subsidiaries plans funds deposited trustees annuities purchased group contracts reserves provided company fund retiree health care benefits advance right modify plans future company uses date consolidated financial statements december january respectively measurement date us international retirement benefit plans net periodic benefit costs companys defined benefit retirement plans benefit plans include following components retirement plans benefit plans dollars millions service cost interest cost expected return plan assets amortization prior service cost credit amortization net transition obligation recognized actuarial losses curtailments settlements net periodic benefit cost amounts expected recognized net periodic benefit cost coming year companys defined benefit retirement plans postretirement plans dollars millions amortization net transition obligation amortization net actuarial losses amortization prior service cost unrecognized gains losses us pension plans amortized average remaining future service plan plans active employees amortized average life expectancy amortization gains johnson johnson annual report losses us benefit plans determined using corridor greater market value assets projected benefit obligation total unamortized gains losses excess corridor amortized average remaining future service prior service costsbenefits us pension plans amortized remaining future service plan participants time plan amendment prior service costbenefit us benefit plans amortized average remaining service full eligibility age plan participants time plan amendment weightedaverage assumptions following table represent rates used develop actuarial present value projected benefit obligation year listed also net periodic benefit cost following year retirement plans benefit plans worldwide benefit plans discount rate expected longterm rate return plan assets rate increase compensation levels companys discount rates determined considering current yield curves representing high quality longterm fixed income instruments resulting discount rates consistent duration plan liabilities expected rates return plan asset assumptions represent company 's assessment longterm returns diversified investment portfolios globally assessment determined using projections external financial sources longterm historical averages actual returns asset class various asset class allocations market following table displays assumed health care cost trend rates individuals health care plans health care cost trend rate assumed next year rate cost trend rate assumed decline ultimate trend year rate reaches ultimate trend rate onepercentagepoint change assumed health care cost trend rates would following effect onepercentage onepercentage dollars millions point increase point decrease health care plans total interest service cost postretirement benefit obligation johnson johnson annual report following table sets forth information related benefit obligation fair value plan assets yearend companys defined benefit retirement plans postretirement plans retirement plans benefit plans dollars millions change benefit obligation projected benefit obligation beginning year service cost interest cost plan participant contributions amendments actuarial losses divestitures acquisitions curtailments settlements restructuring benefits paid plan effect exchange rates projected benefit obligation end year change plan assets plan assets fair value beginning year actual return loss plan assets company contributions plan participant contributions settlements divestitures acquisitions benefits paid plan assets effect exchange rates plan assets fair value end year funded status end year amounts recognized companys balance sheet consist following noncurrent assets current liabilities noncurrent liabilities total recognized consolidated balance sheet end year amounts recognized accumulated comprehensive income consist following net actuarial loss prior service cost credit unrecognized net transition obligation total tax effects accumulated benefit obligations end year johnson johnson annual report retirement plans benefit plans dollars millions changes plan assets benefit obligations recognized comprehensive income net periodic benefit cost net actuarial loss amortization net actuarial loss gain prior service cost amortization prior service cost credit effect exchange rates total recognized comprehensive income tax total recognized net periodic benefit cost comprehensive income company plans continue fund us qualified plans comply pension protection act international plans funded accordance local regulations additional discretionary contributions made deemed appropriate meet longterm obligations plans certain plans funding common practice funding provides economic benefit consequently company several pension plans funded company contributed million million us international pension plans respectively following table displays funded status company 's us qualified nonqualified pension plans international funded unfunded pension plans december january respectively us plans international plans qualified plans nonqualified plans funded plans unfunded plans dollars millions plan assets projected benefit obligation accumulated benefit obligation funded status projected benefit obligation accumulated benefit obligation plans accumulated benefit obligations excess plan assets accumulated benefit obligation projected benefit obligation plan assets billion billion billion respectively end billion billion billion respectively end following table displays projected future benefit payments companys retirement benefit plans dollars millions projected future benefit payments retirement plans benefit plans gross medicare rebates benefit plans net following table displays projected future minimum contributions companys us international unfunded retirement plans amounts include discretionary contributions company may elect make future johnson johnson annual report dollars millions projected future contributions unfunded us retirement plans unfunded international retirement plans pension plan overseen local committee board responsible overall administration investment pension plans determining investment policies strategies goals committee board considers factors including local pension rules regulations local tax regulations availability investment vehicles separate accounts commingled accounts insurance funds etc funded status plans ratio actives retirees duration liabilities relevant factors including diversification liquidity local markets liquidity base currency majority companys pension funds open new entrants expected ongoing plans permitted investments primarily liquid andor listed little reliance illiquid nontraditional investments hedge funds companys retirement plan asset allocation end target allocations follows percent target plan assets allocation worldwide retirement plans equity securities debt securities total plan assets determination fair value plan assets plan established welldocumented process determining fair values fair value based upon quoted market prices available listed prices quotes available fair value based upon models primarily use inputs marketbased independently sourced market parameters including yield curves interest rates volatilities equity debt prices foreign exchange rates credit curves plan believes valuation methods appropriate consistent market participants use different methodologies assumptions determine fair value certain financial instruments could result different estimate fair value reporting date valuation hierarchy authoritative literature establishes threelevel hierarchy prioritize inputs used measuring fair value levels within hierarchy described table level highest priority level lowest financial instruments categorization within valuation hierarchy based upon lowest level input significant fair value measurement following description valuation methodologies used investments measured fair value shortterm investments cash quoted shortterm instruments valued closing price amount held deposit custodian bank investments investment vehicles valued using net asset value nav provided administrator fund nav based value underlying assets owned fund minus liabilities divided number shares outstanding nav quoted price market active classified level government agency securities limited number investments valued closing price reported major market individual securities traded quoted prices available active market investments classified within level valuation hierarchy quoted market prices available specific security fair values estimated using pricing models quoted prices securities similar characteristics discounted cash flows quoted market prices security available active market classified level debt instruments limited number investments valued closing price reported major market individual securities traded quoted prices available active market investments classified level quoted market prices available specific security fair values estimated using pricing models quoted prices securities similar characteristics discounted cash flows classified level level debt instruments priced based unobservable inputs johnson johnson annual report equity securities common stocks valued closing price reported major market individual securities traded substantially common stock classified within level valuation hierarchy commingled funds investments public investment vehicles valued using nav provided fund administrator nav based value underlying assets owned fund minus liabilities divided number shares outstanding assets level category quoted market price market active insurance contracts instruments issued insurance companies fair value based negotiated value underlying investments held separate account portfolios well considering credit worthiness issuer underlying investments government assetbacked fixed income securities general insurance contracts classified level quoted prices observable inputs pricing assets assets represented primarily limited partnerships real estate investments well commercial loans commercial mortgages classified corporate debt assets exchange listed actively traded classified level inactively traded assets classified level limited partnerships represent investments private equity similar funds valued general partners well assets valued using unobservable inputs classified level following table sets forth retirement plans ' trust investments measured fair value december january quoted prices significant significant active unobserv markets observable able identical assets inputs inputs level level level total assets dollars millions shortterm investment funds government agency securities debt instruments equity securities commingled funds insurance contracts assets trust investments fair value company 's benefit plans unfunded except us commingled funds level million million december january respectively million us shortterminvestment funds level december fair value johnson johnson common stock directly held plan assets million total plan assets december million total plan assets january level gains losses table sets forth summary changes fair value plans level assets years ended december january equity commingled insurance dollars millions debt instruments securities funds contracts assets total level balance january realized gains losses unrealized gains losses purchases sales issuances settlements net balance january realized gains losses unrealized gains losses purchases sales issuances settlements net balance december johnson johnson annual report savings plan company voluntary k savings plans designed enhance existing retirement programs covering eligible employees company matches percentage employees contributions consistent provisions plan heshe eligible total company matching contributions plans million million million respectively capital treasury stock changes treasury stock treasury stock amounts millions except treasury stock shares thousands shares amount balance january employee compensation stock option plans repurchase common stock balance january employee compensation stock option plans repurchase common stock balance january employee compensation stock option plans issuance common stock associated acquisition synthes inc repurchase common stock balance december aggregate shares common stock issued approximately shares end cash dividends paid per share compared dividends per share per share includes repurchase common stock associated acquisition synthes inc accumulated comprehensive income components comprehensive incomeloss consist following total gains accumulated foreign gains losses currency losses employee benefit derivatives comprehensive dollars millions translation securities plans hedges incomeloss january net changes january net changes january net changes december amounts accumulated comprehensive income presented net related tax impact foreign currency translation adjusted income taxes relates permanent investments international subsidiaries additional details comprehensive income see consolidated statements comprehensive income international currency translation translation subsidiaries operating nonus dollar currencies company determined local currencies international subsidiaries functional currencies except highly inflationary economies defined compound cumulative rates inflation past three years substantial portion cash flows local currency consolidating international subsidiaries balance sheet currency effects recorded component accumulated johnson johnson annual report comprehensive income equity account includes results translating balance sheet assets liabilities current exchange rates except located highly inflationary economies translation balance sheet accounts highly inflationary economies reflected operating results rollforward changes foreign currency translation adjustments included note net currency transaction gains losses included income expense losses million million million respectively earnings per share following reconciliation basic net earnings per share diluted net earnings per share fiscal years ended december january january millions except per share amounts basic net earnings per share attributable johnson johnson average shares outstanding basic potential shares exercisable stock option plans less shares repurchased treasury stock method convertible debt shares accelerated share repurchase program adjusted average shares outstanding diluted diluted net earnings per share attributable johnson johnson diluted net earnings per share calculation includes dilutive effect convertible debt offset related reduction interest expense million aftertax years diluted net earnings per share excludes million million million shares underlying stock options respectively exercise price options greater average market value would result antidilutive effect diluted earnings per share diluted earnings per share calculation fiscal year ended december included dilutive effect million shares related accelerated share repurchase program associated acquisition synthes inc see note consolidated financial statements additional details increasedecrease volume weighted average share price would impact estimate approximately million shares rental expense lease commitments rentals space vehicles manufacturing equipment office data processing equipment operating leases approximately million million million respectively approximate minimum rental payments required operating leases initial remaining noncancelable lease terms excess one year december dollars millions total commitments capital leases significant common stock stock option plans stock compensation agreements december company stockbased compensation plans shares outstanding contracts company 's stock option plan longterm incentive plan longterm incentive plan scios inc stock option plans longterm incentive plan expired april options restricted shares granted subsequent date longterm incentive plan compensation cost charged income plans million million million respectively total income tax benefit recognized income statement sharebased compensation costs million million million respectively total unrecognized compensation cost million million million respectively weighted average period cost recognized years years years respectively sharebased compensation costs capitalized part inventory insignificant periods johnson johnson annual report stock options stock options expire years date grant vest service periods range months years options granted average high low prices companys common stock new york stock exchange date grant longterm incentive plan company may issue million shares common stock plus shares canceled expired forfeited issued longterm incentive plan subsequent april shares available future grants longterm incentive plan million end company settles employee stock option exercises treasury shares previously treasury shares replenished throughout year number shares used settle employee stock option exercises however pursuant accelerated stock repurchase agreements connection acquisition synthes inc company made purchases common stock open market fiscal third fourth quarters fair value option award estimated date grant using blackscholes option valuation model uses assumptions noted following table expected volatility represents blended rate year daily historical average volatility rate week average implied volatility rate based atthemoney traded johnson johnson options life years historical data used determine expected life option riskfree rate based us treasury yield curve effect time grant average fair value options granted respectively fair value estimated based weighted average assumptions riskfree rate expected volatility expected life years dividend yield summary option activity plan december january january changes years ending dates presented aggregate intrinsic weighted value shares thousands outstanding shares average exercise price dollars millions shares january options granted options exercised options canceledforfeited shares january options granted options exercised options canceledforfeited shares january options granted options exercised options canceledforfeited shares december total intrinsic value options exercised million million million respectively johnson johnson annual report following table summarizes stock options outstanding exercisable december shares thousands outstanding exercisable average exercise average exercise exercise price range options average life price options price average contractual life remaining years stock options exercisable january january average price average life years average price average life years respectively restricted share units performance share units company grants restricted share units vesting period three years company also grants performance share units paid shares johnson johnson common stock end threeyear performance period whether performance share units vest amount vest tied achievement threeyear period three equallyweighted goals directly align help drive longterm total shareholder return sales adjusted operational earnings per share relative total shareholder return number shares actually earned end threeyear period vary based actual performance target number performance share units granted company settles employee stock issuances treasury shares previously treasury shares replenished throughout year number shares used settle employee stock issuances however pursuant accelerated stock repurchase agreements connection acquisition synthes inc company made purchases common stock open market fiscal third fourth quarters summary restricted share units performance share units activity plans december presented outstanding restricted outstanding shares thousands share units performance share units shares january granted issued canceledforfeited shares january granted issued canceledforfeited shares january granted issued canceledforfeited shares december average fair value restricted share units granted respectively using fair market value date grant fair value restricted share units discounted dividends paid restricted share units vesting period fair value restricted share units settled million million million respectively johnson johnson annual report weighted average fair value performance share units calculated using weighted average fair market value three component goals date grant fair values sales earnings per share goals performance share unit estimated date grant using fair market value shares time award discounted dividends paid performance share units vesting period fair value relative total shareholder return goal performance share unit estimated date grant using monte carlo valuation model performance share units issued johnson johnson annual report segments business geographic areas sales customers dollars millions consumer united states international total pharmaceutical united states international total medical devices diagnostics united states international total worldwide total pretax profit identifiable assets dollars millions consumer pharmaceutical medical devices diagnostics total less expense allocated segments general corporate worldwide total additions property depreciation plant equipment amortization dollars millions consumer pharmaceutical medical devices diagnostics segments total general corporate worldwide total johnson johnson annual report sales customers longlived assets dollars millions united states europe western hemisphere excluding us asiapacific africa segments total general corporate non longlived assets worldwide total see note description segments company operates export sales significant company customer represented total revenues amounts allocated segments include interest income expense noncontrolling interests general corporate income expense includes expense billion billion currency related expense related acquisition synthes inc respectively general corporate includes cash marketable securities includes million net litigation expense includes product liability comprised million million pharmaceutical medical devices diagnostics segments respectively includes million inprocess research development expense comprised million million pharmaceutical medical devices diagnostics segments respectively includes million synthes integrationtransaction costs medical devices diagnostics segment includes million asset writedowns adjustments comprised million million million pharmaceutical consumer medical devices diagnostics segments respectively medical devices diagnostics segment also includes million expense cost associated depuy asr hip program includes million net litigation expense includes product liability comprised million million pharmaceutical medical devices diagnostics segments respectively includes million net restructuring expense comprised million expense medical devices diagnostics segment gain million pharmaceutical segment medical devices diagnostics segment also includes million expense cost associated depuy asr hip program includes million net litigation gain includes product liability expense comprised million expense pharmaceutical segment gain million medical devices diagnostics segment medical devices diagnostics segment also includes million expense cost associated depuy asr hip program longlived assets include property plant equipment net respectively intangible assets goodwill net respectively johnson johnson annual report selected quarterly financial data unaudited selected unaudited quarterly financial data years summarized second dollars millions except per share data first quarter second q uarter third q uarter fourth q uarter first q uarter quarter third q uarter fourth q uarter segment sales customers consumer pharmaceutical med devices diagnostics total sales gross profit earnings provision taxes income net earnings attributable johnson johnson basic net earnings per share attributable johnson johnson diluted net earnings per share attributable johnson johnson first quarter includes aftertax gain million currency costs associated acquisition synthes inc second quarter includes aftertax charges million asset writedowns million net litigation million associated acquisition synthes inc million impairment inprocess research development third quarter includes aftertax charges million associated acquisition synthes inc million impairment inprocess research development million associated litigation including product liability million associated depuy asr hip program fourth quarter includes aftertax charges million net litigation including product liability million associated acquisition synthes inc million associated depuy asr hip program million impairment inprocess research development first quarter includes aftertax charge million net litigation including product liability depuy asr hip program second quarter includes aftertax charges million restructuring million litigation including product liability depuy asr hip program partially offset million aftertax gain associated adjustment value currency option related acquisition synthes inc third quarter includes million aftertax charge associated adjustment value currency option deal costs related acquisition synthes inc fourth quarter includes aftertax charges million net litigation including product liability million cost associated depuy asr hip program million associated adjustment value currency option deal costs related acquisition synthes inc business combinations divestitures certain businesses acquired million cash stock million liabilities assumed acquisitions accounted purchase method accordingly results operations included financial statements respective dates acquisition acquisitions included synthes inc global developer manufacturer orthopaedics devices guangzhou biosesal biotech co ltd developer biologic combinations addressing moderate severe hemostasis angiotech pharmaceuticals inc intellectual property know related quilltm knotless tissueclosure device corlmmun inc developer phase ii treatment chf calibra medical inc developer unique wearable threeday insulin patch convenient discreet mealtime dosing people diabetes take multiple daily injections insulinspectrum vision llc full service distributor contact lenses serving russia facilities ukraine kazakhstan marketing authorizations trademarks patents extending zyrtec related market rights australia canada johnson johnson annual report excess purchase price estimated fair value tangible assets acquired amounted million assigned identifiable intangible assets residual recorded goodwill amount approximately million identified value iprd associated acquisitions corlmmun inc synthes inc iprd related acquisition synthes inc million associated orthopaedic devices iprd associated corlmmun million related chf treatment iprd values calculated using cash flow projections discounted risk inherent projects synthes inc probability success factor discounted using rate corlmmun probability success factor discounted using rate fiscal second quarter company completed acquisition synthes inc global developer manufacturer orthopaedics devices purchase price billion cash stock net acquisition cost transaction billion based cash hand closing billion terms agreement share synthes inc common stock exchanged chf cash shares johnson johnson common stock based calculated exchange ratio exchange ratio calculated june based relevant exchange rate closing price johnson johnson common stock date total fair value consideration transferred billion acquisition completed june based relevant exchange rate closing price johnson johnson common stock date total fair value consideration transferred billion janssen pharmaceutical company organized laws ireland whollyowned subsidiary johnson johnson used cash hand satisfy cash portion merger consideration stock portion merger consideration consisted shares johnson johnson common stock purchased janssen pharmaceutical two banks pursuant two accelerated share repurchase asr agreements dated june june janssen pharmaceutical purchased aggregate approximately million shares johnson johnson common stock initial purchase price billion asr agreements shares delivered janssen pharmaceutical june final settlement transactions asr agreement expected occur first half may occur earlier option two banks applicable later certain circumstances based theoretical settlement asr agreements additional million shares would issued settle asr agreements december addition company believes transactions asr agreement series related internal transactions consummated tax efficient mannerin accordance applicable law possible internal revenue service could assert one contrary positions challenge transactions tax perspective challenged amount total purchase price synthes shares could treated subject applicable us tax approximately statutory rate company plus interest following table summarizes consideration transferred acquire synthes inc valued acquisition date june dollars millions cash multiply chf shares synthes common stock outstanding exchange ratea common stock multiply shares synthes common stock outstanding jj stock priceb total fair value consideration transferred synthes common stock outstanding million shares acquisition date chfusd exchange rate b johnson johnson closing stock price new york stock exchange acquisition date per share company still finalizing allocation purchase price individual assets acquired liabilities assumed allocation purchase price included current period balance sheet based best estimate management assist management allocation company engaged valuation specialists prepare independent appraisals certain estimated values surrounding litigation loss contingencies yet finalized subject change finalize amounts recognized obtain information necessary complete analysis expect finalize amounts soon possible later one year acquisition date following table presents amounts recognized assets acquired liabilities assumed acquisition date well adjustments made december johnson johnson annual report dollars millions june december cash cash equivalents inventory accounts receivable net current assets property plant equipment goodwill intangible assets noncurrent assets total assets acquired current liabilities deferred taxes noncurrent liabilities total liabilities assumed net assets acquired adjustments made since date acquisition account changes inventory based results physical inventory counts deferred taxes reflect statutory tax rate applied intangible assets revisions purchase price allocation material statements consolidated earnings prior fiscal quarters assets acquired recorded medical devices diagnostics segment acquisition synthes inc resulted billion goodwill goodwill primarily attributable synergies expected arise acquisition synthes inc goodwill expected deductible tax purposes purchase price allocation identifiable intangible assets included june december balance sheets follows dollars millions june december intangible assets definite lives customer relationships patents technology total amortizable intangibles trademark trade name inprocess research development total intangible assets weighted average life billion total amortizable intangibles approximately years trade name asset values determined indefinite life based number factors including trade name history competitive environment market share future operating plans intangible assets definite lives assigned asset lives ranging years majority intangible asset valuation relates customer relationships patents technology trade name intangible assets company 's trauma cranio maxillofacial spine power tools business lines additionally inprocess research development intangible assets valued technology programs unapproved products value iprd calculated using cash flow projections discounted risk inherent projects discount rate applied johnson johnson annual report company process executing integration plans combine businesses sales organizations systems locations result company continue incur integration costs operating results synthes reported company 's financial statements beginning june total sales net earnings synthes fiscal year ended december million million respectively following table provides pro forma results operations fiscal year ended december january synthes inc acquired january pro forma results include effect divestitures certain purchase accounting adjustments estimated changes depreciation amortization expense acquired tangible intangible assets however pro forma results include anticipated cost savings effects integration synthes inc accordingly amounts necessarily indicative results acquisition occurred dates indicated may occur future unaudited pro forma consolidated results dollars millions except per share amounts net sales net earnings attributable johnson johnson diluted net earnings per share attributable johnson johnson company recorded acquisition related costs million tax recorded cost products sold income expense connection synthes acquisition depuy orthopaedics inc agreed divest certain rights assets related trauma business biomet inc completed initial closing transaction fiscal second quarter including countries represented majority sales december transaction closed worldwide certain businesses acquired million cash million liabilities assumed acquisitions accounted purchase method accordingly results operations included financial statements respective dates acquisition acquisitions included crucell nv global biopharmaceutical company focused research development production marketing vaccines antibodies infectious disease worldwide overthecounter brands jb chemicals pharmaceuticals limited including rinza russia 's leading multisymptom cough cold brand doktor mom russia 's number two selling cough brand well several brands full ownership johnson johnsonmerck consumer pharmaceuticals co joint venture us merck sharp dohme corp sterilmed inc leader reprocessing remanufacturing medical devices us excess purchase price estimated fair value tangible assets acquired amounted million assigned identifiable intangible assets residual recorded goodwill amount approximately million identified value iprd associated acquisition crucell nv iprd related acquisition crucell nv million associated vaccines antibodies prevent andor treat infectious diseases value iprd calculated using cash flow projections discounted risk inherent projects probability success factors ranging used reflect inherent clinical regulatory risk discount rate applied fiscal second quarter company recorded charge billion intangible asset writedown billion impairment inprocess research development related crucell business certain businesses acquired million cash million liabilities assumed acquisitions accounted purchase method accordingly results operations included financial statements respective dates acquisition acquisitions included acclarent inc privately held medical technology company dedicated designing developing commercializing devices address conditions affecting ear nose throat ent respivert ltd privately held drug discovery company focused developing smallmolecule inhaled therapies treatment pulmonary diseases micrus endovascular llc global developer manufacturer minimally invasive devices hemorrhagic ischemic stroke excess purchase price estimated fair value tangible assets acquired amounted million assigned identifiable intangible assets residual recorded goodwill amount approximately million identified value iprd associated acquisitions acclarent inc respivert ltd johnson johnson annual report micrus endovascular llc iprd related acquisition acclarent inc million associated novel endoscopic catheterbased devices meet needs ent patients value iprd calculated using cash flow projections discounted risk inherent projects probability success factors ranging used reflect inherent clinical regulatory risk discount rate applied iprd related acquisition respivert ltd million associated narrow spectrum kinase inhibitors unique profile antiinflammatory activities treatments moderate severe asthma chronic obstructive pulmonary disease copd cystic fibrosis cf value iprd calculated using cash flow projections discounted risk inherent projects probability success factors ranging used reflect inherent clinical regulatory risk discount rate applied iprd related acquisition micrus endovascular llc million associated ischemic flow diverter technologies value iprd calculated using cash flow projections discounted risk inherent projects probability success factors ranging used reflect inherent clinical regulatory risk discount rate applied exception synthes inc acquisition supplemental pro forma information accordance us gaap standards related business combinations goodwill intangible assets provided impact aforementioned acquisitions material effect companys results operations cash flows financial position company divestitures included bystolic nebivolol ip rights forest laboratories inc trauma business depuy orthopaedics inc biomet inc therakos business affiliate gores capital partners iii lp sale certain consumer brands rhogam business gains divestitures businesses billion company divestitures included animal health business elanco division eli lilly monistat canada us territories including puerto rico assets ortho dermatologics division us subsidiaries valeant pharmaceuticals international inc surgical instruments business codman shurtleff inc gains divestitures businesses billion company divestitures included breast care business ethicon endosurgery inc gains divestitures recognized incomeexpense net legal proceedings johnson johnson certain subsidiaries involved various lawsuits claims regarding product liability intellectual property commercial matters governmental investigations legal proceedings arise time time ordinary course business company records accruals contingencies probable liability incurred amount loss reasonably estimated december company determined liabilities associated certain litigation matters probable reasonably estimated company accrued matters continue monitor related legal issue adjust accruals new information developments accordance asc litigation regulatory matters currently disclosed loss probable reasonably possible company unable determine estimate possible loss range loss beyond amounts already accrued matters affected various factors including whether damages sought proceedings unsubstantiated indeterminate scientific legal discovery commenced complete proceedings early stages matters present legal uncertainties significant facts dispute numerous parties involved company 's opinion based examination matters experience date discussions counsel ultimate outcome legal proceedings net liabilities accrued company 's balance sheet expected material adverse effect company 's financial position however resolution reporting period one matters either alone aggregate may material adverse effect company 's results operations cash flows period product liability certain subsidiaries johnson johnson involved numerous product liability cases damages claimed substantial subsidiaries confident adequacy warnings instructions use accompany products issue feasible predict ultimate outcome litigation company established product liability accruals compliance asc based currently available information cases may limited changes accruals may required future additional information becomes available multiple products johnson johnson subsidiaries subject product liability claims lawsuits claimants seek substantial compensatory available punitive damages including levaquin asr xl acetabular system depuy asr hip resurfacing system pinnacle acetabular cup system risperdal johnson johnson annual report pelvic meshes duragesicfentanyl patches topamax december us approximately plaintiffs direct claims pending lawsuits regarding injuries allegedly due levaquin respect asr xl acetabular system depuy asr hip resurfacing system respect pinnacle acetabular cup system respect risperdal respect pelvic meshes respect duragesicfentanyl patches respect topamax august depuy orthopaedics inc depuy announced worldwide voluntary recall asr xl acetabular system depuy asr hip resurfacing system used hip replacement surgery claims personal injury made depuy johnson johnson number pending lawsuits continues increase cases filed federal courts united states organized multidistrict litigation united states district court northern district ohio litigation also filed countries outside united states primarily united kingdom canada australia company continues receive information respect potential costs associated recall fiscal third fourth quarters company increased accruals depuy asr hip recall program related product liability company completed analysis new information including number expected claims recently updated revision rates recalled products product liability expense per case changes accruals may required future additional information becomes available claims personal injury also made depuy johnson johnson relating depuy 's pinnacle acetabular cup system number pending product liability lawsuits continues increase company continues receive information respect potential costs anticipated number cases cases filed federal courts united states organized multidistrict litigation united states district court northern district texas company established product liability accrual anticipation product liability litigation associated depuy 's pinnacle acetabular cup system changes accrual may required future additional information becomes available claims personal injury made ethicon inc ethicon johnson johnson arising ethicon 's pelvic mesh devices used treat stress urinary incontinence pelvic organ prolapse number pending product liability lawsuits continues increase company continues receive information respect potential costs anticipated number cases cases filed federal courts united states organized multidistrict litigation united states district court southern district west virginia addition class action several individual personal injury cases commenced canada australia seeking damages alleged injury resulting ethicon 's pelvic mesh devices company established product liability accrual anticipation product liability litigation associated ethicon 's pelvic mesh products changes accrual may required future additional information becomes available company believes ultimate resolution matters based historical reasonably likely future trends expected material adverse effect company 's financial position annual results operations cash flows resolution interim reporting period could material impact company 's results operations cash flows period intellectual property certain subsidiaries johnson johnson subject time time legal proceedings claims related patent trademark intellectual property matters arising business significant matters described patent infringement certain subsidiaries johnson johnson involved lawsuits challenging coverage andor validity patents products although subsidiaries believe substantial defenses challenges respect material patents assurance outcome matters loss cases could potentially adversely affect ability subsidiaries sell products require payment past damages future royalties medical devices diagnostics october tyco healthcare group lp tyco us surgical corporation filed lawsuit ethicon endosurgery inc ees united states district court district connecticut alleging several features ees 's harmonic scalpel infringed four tyco patents october motions summary judgment prior initial trial number claims found invalid number found infringed however claim found valid infringed trial commenced december court dismissed case without prejudice grounds tyco patents suit dismissal without prejudice affirmed appeal january tyco filed another complaint united states district court district connecticut asserting infringement three four patents johnson johnson annual report previous lawsuit adding new products tyco seeking monetary damages injunctive relief case tried july parties awaiting decision court october bruce saffran saffran filed patent infringement lawsuit johnson johnson cordis corporation cordis united states district court eastern district texas alleging infringement us patent january jury returned verdict finding cordis 's sales cypher stent willfully infringed ' patent jury awarded saffran million march court entered judgment cordis amount million representing jury verdict plus million prejudgment interest cordis appealed judgment oral argument heard december decision court appeals pending company believes potential unfavorable outcome probable established accrual respect case november roche diagnostics operations inc et al roche filed patent infringement lawsuit lifescan inc lifescan united states district court district delaware accusing lifescan 's entire onetouch line blood glucose monitoring systems infringement two patents related use microelectrode sensors september lifescan obtained favorable ruling claim construction precluded finding infringement court entered judgment roche july roche appealed court appeals reversed district court 's ruling claim construction remanded case district court new findings issue parties awaiting ruling claim construction roche seeking monetary damages injunctive relief june rembrandt vision technologies lp rembrandt filed patent infringement lawsuit johnson johnson vision care inc jjvc united states district court eastern district texas alleging jjvc 's manufacture sale acuvueadvance acuvue oasys hydrogel contact lenses infringe us patent chang patent rembrandt seeking monetary relief case transferred united states district court middle district florida may jury returned verdict holding neither accused lenses infringe ' patent rembrandt filed appeal united states court appeals federal circuit november howmedica osteonics corp howmedica stryker ireland ltd stryker filed patent infringement lawsuit depuy orthopaedics inc depuy united states district court district new jersey alleging infringement depuy 's pinnacle acetabular cup system duraloc acetabular cup system patent relating duallocking mechanism feature acetabular cup system howmedica stryker seeking monetary damages injunctive relief depuy filed answer february filed counterclaim asserting stryker 's trident acetabular hip system infringes depuy 's us patent depuy seeking damages injunctive relief howmedica stryker may medtronic minimed inc medtronic puerto rico operations co minimed distribution corp collectively medtronic minimed filed patent infringement lawsuit animas corporation united states district court central district california alleging animas ' onetouch ping glucose management system infringes nine patents medtronic minimed seeking monetary damages injunctive relief june depuy orthopaedics inc depuy filed declaratory judgment action orthopaedic hospital oh united states district court northern district indiana seeking declaration parties ' rights obligations patent rights license agreement parties related development polyethylene material oh claimed depuy owes royalties products made antioxidant polyethylene depuy disputes owes royalties oh thus seeking declaration court disputed contractual provisions depuy filed declaratory judgment action oh filed separate suit subject matter united states district court central district california moved consolidation california case pharmaceutical may abbott biotechnology ltd abbott filed patent infringement lawsuit centocor inc centocor janssen biotech inc jbi united states district court district massachusetts alleging simponi infringes abbott 's us patent nos salfeld patents abbott seeking monetary damages injunctive relief april parties participated arbitration issue jbi 's defense abbott equitably estopped asserting patents may arbitrator rejected jbi 's defense case reinstated district court fact discovery ongoing august abbott gmbh co abbott gmbh abbott bioresearch center filed patent infringement lawsuit centocor jbi united states district court district massachusetts alleging stelara infringes two united states patents assigned abbott gmbh jbi filed complaint united states district court district columbia declaratory judgment noninfringement invalidity abbott gmbh patents well complaint review patent interference decision granted priority invention one two asserted patents abbott gmbh cases transferred district columbia district massachusetts trial held september jury verdict favor centocor invalidating abbott 's patent claims posttrial briefing completed parties awaiting decision also august abbott gmbh abbott laboratories limited brought patent infringement lawsuit federal court canada alleging stelara infringes abbott gmbh 's johnson johnson annual report canadian patent trial scheduled december canadian case addition us canadian litigations august abbott filed patent infringement lawsuits netherlands switzerland germany cases abbott seeking monetary damages injunctive relief litigation filers abbreviated new drug applications andas following summarizes lawsuits pending generic companies filed abbreviated new drug applications andas seeking market generic forms products sold various subsidiaries johnson johnson prior expiration applicable patents covering products andas typically include allegations noninfringement invalidity unenforceability patents event subsidiaries successful actions statutory month stays expire united states district court rulings obtained thirdparty companies involved ability upon approval united states food drug administration fda introduce generic versions products issue resulting substantial market share revenue losses products concerta number generic companies filed andas seeking approval market generic versions concerta september settlement agreement entered kremersurban llc kudco ireland ltd collectively kudco pursuant kudco granted license patentinsuit market generic version concerta starting july kudco obtains fda approval november alza corporation alza orthomcneiljanssen pharmaceuticals inc omjpi janssen pharmaceuticals inc jpi filed patent infringement lawsuit united states district court district delaware impax laboratories inc impax teva pharmaceuticals usa inc teva pharmaceutical industries ltd collectively teva response impax teva 's filing major amendment anda seeking approval market generic version concerta expiration alza jpi 's patent relating concerta impax teva filed counterclaims alleging noninfringement invalidity may alza jpi filed second lawsuit teva response teva 's filing second major amendment anda seeking approval market additional dosage strengths generic concerta product expiration alza jpi 's patent relating concerta cases alza jpi sought order enjoining defendants marketing generic version concerta prior expiration alza jpi 's concerta patent september settlement agreement entered impax teva pursuant parties granted license patentinsuit market generic version concerta starting july earlier certain circumstances obtain fda approval ortho tricyclen lo number generic companies filed andas seeking approval market generic versions ortho tricyclen lo february jpi watson laboratories inc watson pharmaceuticals inc collectively watson entered settlement agreement pursuant settlement agreement parties entered supply agreement whereby jpi supply watson combinational oral contraceptive containing certain specified compounds december earlier certain circumstances expiration ' patent december addition event watson wish exercise rights supply agreement jpi granted watson license market watson 's anda product december earlier certain circumstances december january omjpi jpi filed patent infringement lawsuit lupin ltd lupin pharmaceuticals inc collectively lupin united states district court district new jersey response lupin 's anda seeking approval market generic version ortho tricyclen lo prior expiration jpi 's patent relating ortho tricyclen lo otclo patent lupin filed counterclaim alleging invalidity patent trial concluded june september court issued decision favor jpi particular court ordered effective date approval lupin 's anda previously approved earlier expiration otclo patent lupin appealed decision court appeals federal circuit oral argument heard february court 's decision pending november omjpi jpi filed patent infringement lawsuit mylan inc mylan pharmaceuticals inc collectively mylan famy care ltd famy care united states district court district new jersey response famy care 's anda seeking approval market generic version ortho tricyclen lo prior expiration otclo patent mylan famy care filed counterclaims alleging invalidity patent november jpi mylan entered settlement agreement pursuant mylan granted license otclo patent market generic version ortho tricyclen lo starting december earlier certain circumstances obtain fda approval october jpi filed patent infringement lawsuit sun pharma global fze sun pharmaceutical industries collectively sun united states district court district new jersey response sun 's anda johnson johnson annual report seeking approval market generic version ortho tricyclen lo prior expiration otclo patent may jpi filed patent infringement lawsuit haupt pharma inc ranbaxy laboratories limited ranbaxy inc collectively haupt united states district court district new jersey response haupt 's anda seeking approval market generic version ortho tricyclen lo prior expiration otclo patent december jpi haupt entered settlement agreement pursuant haupt granted license otclo patent market generic version ortho tricyclen lo starting december earlier certain circumstances obtain fda approval august jpi filed patent infringement lawsuit glenmark generics ltd glenmark generics inc usa collectively glenmark united states district court district new jersey response glenmark 's anda seeking approval market generic version ortho tricyclen lo prior expiration otclo patent november settlement agreement entered glenmark pursuant glenmark granted license otclo patent market generic version ortho tricyclen lo starting december earlier certain circumstances obtain fda approval cases jpi sought seeking order enjoining defendants marketing generic versions ortho tricylcen lo expiration otclo patent prezista number generic companies filed andas seeking approval market generic versions prezista november tibotec inc tibotec llc tibotec pharmaceuticals janssen rd ireland collectively tibotec filed patent infringement lawsuit lupin ltd lupin pharmaceuticals inc collectively lupin mylan inc mylan pharmaceuticals inc collectively mylan united states district court district new jersey response lupin 's mylan 's respective andas seeking approval market generic versions tibotec 's prezista product expiration tibotec 's patent relating prezista lupin mylan filed counterclaims alleging noninfringement invalidity july tibotec filed another patent infringement lawsuit lupin united states district court district new jersey response lupin 's supplement anda add new dosage strengths proposed product august tibotec gd searle company gd searle filed patent infringement lawsuit lupin mylan response notice letters advising andas seeking approval market generic versions tibotec 's prezista product expiration two patents relating prezista tibotec exclusively licenses gd searle march tibotec gd searle filed patent infringement lawsuit teva pharmaceuticals usa inc teva pharmaceuticals ltd collectively teva united states district court district new jersey response teva 's anda seeking approval market generic version prezista expiration certain patents relating prezista tibotec either owns exclusively licenses gd searle march tibotec filed patent infringement lawsuit hetero drugs ltd unit iii hetero usa inc collectively hetero united states district court district new jersey response hetero 's anda seeking approval market generic version prezista expiration certain patents relating prezista tibotec exclusively licenses gd searle july upon agreement parties court entered stay lawsuit pending final decision lawsuit teva respect validity andor enforceability patents tibotec licenses gd searle hetero agreeing bound final decision september court consolidated lawsuits well lawsuits brought united states government defendants infringement united states governmentowned patent relating prezista purposes pretrial discovery trial proviso discovery completed party move cases deconsolidated trial may june janssen products lp janssen rd ireland collectively janssen gd searle filed patent infringement lawsuit lupin teva mylan united states district court district new jersey alleging infringement newly issued united states reissue patent janssen exclusively licenses gd searle august janssen gd searle filed patent infringement lawsuit lupin teva mylan united states district court district new jersey alleging infringement newly issued united states reissue patent janssen exclusively licenses gd searle cases consolidated lawsuits october janssen filed motion file supplemental complaint lupin teva mylan united states district court district new jersey alleging infringement united states patent nos mylan lupin teva lupin teva january court permitted three additional patents added consolidated action lawsuits tibotec janssen seeking order enjoining defendants marketing generic versions prezista expiration relevant patents johnson johnson annual report intellectual property matters september centocor ortho biotech products lp janssen products lp jplp intervened inventorship lawsuit filed university kansas center research inc kucr united states america usa united states district court district kansas kucr alleges two kucr scientists added inventors two usaowned patents relating velcade usa licensed patents foreign counterparts millennium pharmaceuticals inc mpi turn sublicensed patents foreign counterparts jplp commercial marketing outside united states july parties reached settlement agreement resolve disputes case submitted inventorship issue arbitration outcome would determine whether prespecified payments would made kucr affect jplp 's right market velcade arbitration took place december decision favor kucr issued march result jplp required make aforementioned prespecified payments kucr december state israel filed lawsuit district court tel aviv jaffa omrix biopharmaceuticals inc various affiliates omrix lawsuit state claims employee governmentowned hospital inventor several patents related fibrin glue technology employee developed government employee state claims right transfer intellectual property omrix belongs state state seeking damages plus royalties quixil evicel products alternatively transfer patents state january genentech inc genentech initiated arbitration ucb celltech celltech seeking damages allegedly cooperating centocor inc janssen biotech inc jbi improperly terminate prior agreement jbi sublicensed genentech 's cabilly patents sell remicade jbi indemnity agreement celltech celltech asserted jbi would liable damages celltech may required pay genentech arbitration following arbitration hearing june arbitrators issued decision finding liability celltech therefore jbi liable potential indemnity claim jbi moved recover attorneys fees costs expenses march noramco inc noramco moved intervene three patent infringement lawsuits filed united states district court southern district new york sdny purdue pharma lp others purdue noramco oxycodone customers impax laboratories inc impax teva pharmaceuticals usa inc teva amneal pharmaceuticals llc amneal february noramco appeared behalf noramco customers watson laboratories inc florida andrx labs llc collectively watsonandrx similar lawsuit filed purdue sdny lawsuits response defendants ' respective andas seeking approval market generic extended release oxycodone products expiration certain purdue patents three asserted patents relate oxycodone processes making oxycodone noramco agreed defend lawsuits behalf impax teva amneal watsonandrx although noramco participate november trial lawsuit brought purdue another noramco customer actavis elizabeth llc actavis took place active ingredient issue actavis lawsuit active ingredient issue lawsuits district court 's decision actavis case may affect lawsuits decision district court actavis case pending august dr james swanson swanson filed lawsuit alza corporation alza northern district california seeking added inventor two alzaowned patents relating concerta alternatively dr swanson alleged patentsinsuit invalid andor unenforceable result alza 's alleged omission dr swanson named inventor patents dr swanson seeking damages award unjust enrichment alza filed motion dismiss swanson 's claims oral argument scheduled february government proceedings like companies pharmaceutical medical devices diagnostics industries johnson johnson certain subsidiaries subject extensive regulation national state local government agencies united states countries operate result interaction government agencies ongoing significant litigation brought investigations conducted government agencies listed possible criminal charges substantial fines andor civil penalties damages could result government investigations litigation average wholesale price awp litigation johnson johnson several pharmaceutical subsidiaries jj awp defendants along numerous pharmaceutical companies defendants series lawsuits state federal courts involving allegations pricing marketing certain pharmaceutical products amounted fraudulent otherwise actionable conduct among things companies allegedly reported inflated average wholesale price awp drugs issue payors alleged used awps calculating provider reimbursement levels many cases federal actions state actions removed federal court consolidated pretrial purposes multidistrict litigation mdl johnson johnson annual report united states district court district massachusetts plaintiffs cases included three classes private persons entities paid portion purchase drugs issue based awp state government entities made medicaid payments drugs issue based awp june trial merits mdl court dismissed claims two plaintiff classes jj awp defendants march court dismissed claims third class jj awp defendants without prejudice awp cases brought various attorneys general proceeded trial manufacturers several state cases certain subsidiaries johnson johnson settled including kentucky set trial january kansas set trial march louisiana mississippi set trial october illinois set trial may alaska set trial july state cases likely set trial due course addition awp case jj awp defendants brought commonwealth pennsylvania tried commonwealth court october november court found commonwealth 's favor regard certain claims pennsylvania unfair trade practices consumer protection law utpl entered injunction awarded million restitution million civil penalties court found jj awp defendants ' favor commonwealth 's claims unjust enrichment misrepresentationfraud civil conspiracy certain commonwealth 's claims utpl jj awp defendants appealed commonwealth court 's utpl ruling pennsylvania supreme court company believes jj awp defendants strong arguments supporting appeal company believes potential unfavorable outcome probable established accrual respect verdict risperdal january janssen pharmaceutica inc janssen pharmaceutica janssen pharmaceuticals inc jpi received subpoena office inspector general united states office personnel management seeking documents concerning sales marketing payments physicians connection sales marketing clinical trials risperdal documents subsequent also requested department justice additional subpoena seeking information marketing adverse reactions risperdal received united states attorney 's office eastern district pennsylvania november numerous subpoenas seeking testimony various witnesses grand jury also received jpi cooperated responding requests documents witnesses united states department justice united states attorney 's office eastern district pennsylvania government continuing actively pursue criminal civil actions february government served civil investigative demands seeking additional information relating sales marketing risperdal sales marketing invega focus matters alleged promotion risperdal invega offlabel uses government notified jpi also pending qui tam actions alleging offlabel promotion risperdal government informed jpi intervene qui tam actions file superseding complaint discussions resolve criminal penalties food drug cosmetic act related promotion risperdal resulted agreement principle united states attorney 's office eastern district pennsylvania key issues relevant disposition criminal charges pursuant single misdemeanor violation food drug cosmetic act certain issues remain open settlement finalized company accrued amounts cover financial component proposed criminal settlement company also reached agreement principle united states department justice settle three pending civil false claims act matters pending eastern district pennsylvania concerning sales marketing risperdal invega northern district california regarding sales marketing natrecor discussed separately district massachusetts alleging defendants provided omnicare inc omnicare longterm care pharmacy rebates payments regarding risperdal products discussed separately assuming agreements finalized resolve federal government 's claims federal false claims act resolve pending state federal government litigation regarding omnicare natrecor settle risperdal medicaidrelated claims states opt settlement tentative settlement agreements described issues remain open must resolved settlements finalized company accrued amounts including additional accrual made second quarter cover tentative settlement agreements however settlements resolve pending state litigation matters regarding risperdal states may elect opt settlements extent state claim elect opt settlements company accrued amount equal state would receive participating settlements among states arkansas louisiana south carolina expected participate settlements discussed company believes strong arguments appeal cases company accrued amount equal states would receive participated settlements addition attorneys general multiple states including alaska arkansas louisiana massachusetts mississippi johnson johnson annual report montana new mexico south carolina utah pending actions janssen pharmaceutica jpi seeking one following remedies reimbursement medicaid public funds risperdal prescriptions written offlabel use compensation treating citizens alleged adverse reactions risperdal civil fines penalties damages overpayments state others violations state consumer fraud statutes punitive damages relief relating alleged unfair business practices certain actions also seek injunctive relief relating promotion risperdal january jpi settled lawsuit filed attorney general texas april lawsuit brought attorney general arkansas jury found jpi johnson johnson court imposed penalties amount approximately billion jpi johnson johnson filed appeal believe strong arguments supporting appeal january court awarded attorney fees approximately million judgment also appealed attorney general west virginia commenced suit janssen pharmaceutica jpi based claims alleged consumer fraud duragesic well risperdal jpi found liable damages assessed million jpi filed appeal november west virginia supreme court reversed trial court 's decision december attorney general west virginia dismissed case related risperdal without payment thereafter jpi settled case insofar related duragesic attorney general louisiana filed multicount complaint janssen pharmaceutica jpi johnson johnson later added defendant case tried october issue tried jury whether johnson johnson jpi violated state 's medicaid fraud act act misrepresentations allegedly made mailing november dear health care professional letter regarding risperdal jury returned verdict jpi johnson johnson violated act awarded million damages trial judge subsequently awarded attorney general counsel fees expenses amount million august interlocutory appellate court affirmed judgment january louisiana supreme court accepted johnson johnson jpi 's request appeal oral argument appeal set march office general counsel commonwealth pennsylvania filed lawsuit janssenpharmaceutica jpi multicount complaint related janssen pharmaceutica 's sale risperdal commonwealth 's medicaid program trial occurred june trial judge dismissed case close plaintiff 's evidence commonwealth filed appeal april july pennsylvania appeals court upheld dismissal commonwealth 's case attorney general south carolina filed lawsuit johnson johnson janssen pharmaceutica jpi several counts march matter tried liability time lawsuit limited claims violation south carolina unfair trade practice act including among others questions whether johnson johnson jpi engaged unfair deceptive acts practices conduct trade commerce distributing november dear health care professional letter regarding risperdal use product 's fdaapproved label jury found favor johnson johnson jpi june court awarded civil penalties approximately million jpi appealed judgment company believes strong arguments supporting appeal oral argument appeal set south carolina supreme court march attorneys general approximately states district columbia indicated interest pursuing similar litigation jpi obtained tolling agreement staying running statute limitations pursued investigation jpi regarding potential consumer fraud actions connection marketing risperdal september jpi settled states district columbia nonmedicaid claims connection sales marketing risperdal invega total approximately million amount previously accrued company 's opinion ultimate resolution risperdal matters expected material adverse effect company 's financial position although resolution reporting period could material impact company 's results operations cash flows period omnicare september johnson johnson received subpoena united states attorney 's office district massachusetts seeking documents related sales marketing eight drugs omnicare inc omnicare manager pharmaceutical benefits longterm care facilities april johnson johnson certain pharmaceutical subsidiaries served two civil qui tam cases asserting claims federal false claims act related state law claims alleging defendants provided omnicare rebates alleged kickbacks causing omnicare file false claims medicaid government programs january government intervened cases naming johnson johnson orthomcneiljanssen pharmaceuticals inc janssen pharmaceuticals inc jpi johnson johnson health care systems inc defendants subsequently commonwealth massachusetts virginia kentucky states california indiana intervened action february united states district court district massachusetts dismissed one qui tam case entirely dismissed case part rejecting allegations defendants violated obligation report best price health care program officials claims johnson johnson annual report united states individual states remain pending june parties granted joint motion stay case pending resolution potential settlement discussed risperdal section november lawsuit filed scott bartz former employee united states district court eastern district pennsylvania johnson johnson certain pharmaceutical subsidiaries jj defendants along codefendants mckesson corporation mckesson omnicare inc february plaintiff filed amended complaint thereafter jj defendants ' motion case transferred united states district court district massachusetts currently pending amended complaint alleges variety causes action federal false claims act corresponding state local statutes including jj defendants engaged various improper transactions allegedly designed report false prescription drug prices federal government order reduce jj defendants ' medicaid rebate obligations complaint alleges jj defendants improperly retaliated plaintiff raised allegations internally bartz seeks multiple forms relief including damages reinstatement position seniority status jj defendants subsequently moved dismiss complaint may march district court dismissed bartz 's claims federal false claims act declined exercise supplemental jurisdiction numerous related claims state false claims act statutes district court however denied dismissal motion regard bartz 's claims retaliated violation federal false claims act violation new jersey 's conscientious employee protection act february parties entered settlement agreement resolve bartz 's claims filed joint motion dismiss lawsuit prejudice district court granted motion dismiss claims mcneil consumer healthcare starting june mcneil consumer healthcare division mcneilppc inc mcneil consumer healthcare certain affiliates including johnson johnson companies received grand jury subpoenas united states attorney 's office eastern district pennsylvania requesting documents broadly relating recalls various products mcneil consumer healthcare fda inspections fort washington pennsylvania lancaster pennsylvania manufacturing facilities well certain documents relating recalls small number products subsidiaries addition february government served mcneilppc inc mcneilppc civil investigative demand seeking records relevant investigation determine violation federal false claims act companies cooperating united states attorney 's office responding subpoenas companies also received civil investigative demands multiple state attorneys general offices broadly relating mcneil recall issues companies continue cooperate inquiries january oregon attorney general filed civil complaint johnson johnson mcneilppc mcneil healthcare llc state court alleging civil violations oregon unlawful trade practices act relating earlier recall mcneil otc product november state court granted motion companies dismiss oregon 's complaint entirety prejudice december oregon filed notice appeal court appeals state oregon march united states filed complaint injunctive relief united states district court eastern district pennsylvania mcneilppc two employees alleging mcneilppc violation fda regulations regarding manufacture drugs facilities operates lancaster pennsylvania fort washington pennsylvania las piedras puerto rico day parties filed consent decree permanent injunction resolving claims set forth complaint court approved entered consent decree march consent decree subject ongoing enforcement court requires mcneilppc take enhanced measures remediate three facilities fort washington facility voluntarily shut april remain shut thirdparty consultant certifies operations compliance applicable law fda concurs thirdparty certification lancaster las piedras facilities may continue manufacture distribute drugs provided third party reviews manufacturing records selected batches drugs released facilities certifies deviations reviewed adversely affect quality selected batches mcneilppc submitted workplan fda remediation lancaster las piedras facilities plan approved fda october thirdparty batch record review may cease fda stated facilities appear compliance applicable law facility subject fiveyear audit period third party facility deemed fda apparent compliance applicable law july scios inc scios received subpoena united states attorney 's office district massachusetts seeking documents related sales marketing natrecor august scios advised investigation would handled united states attorney 's office northern district california san francisco february two qui tam complaints unsealed united states district court northern district california alleging among things improper activities promotion natrecor june united states government intervened one qui tam actions filed complaint scios johnson johnson seeking relief johnson johnson annual report federal false claims act asserting claim unjust enrichment october criminal matter resolved civil case stayed pending resolution potential settlement discussed risperdal section june johnson johnson received subpoena united states attorney 's office district massachusetts relating marketing biliary stents cordis corporation cordis february government informed cordis closing investigation addition january complaint unsealed united states district court northern district texas filed kevin colquitt seeking damages cordis parties alleged violations federal false claims act several similar state laws connection marketing biliary stents united states department justice several states declined intervene january court granted cordis 's motion dismiss claims cordis prejudice plaintiff appealed september synthes inc synthes received civil investigative demand issued pursuant false claims act united states attorney 's office eastern district pennsylvania demand sought information regarding allegations fellowships offered hospitals exchange agreements purchase products synthes produced documents information response demand cooperating inquiry october european commission ec announced opened investigation concerning agreement janssencilag bv janssencilag sandoz bv relating supply fentanyl patches netherlands whether agreement infringes european competition law january ec issued statement objections setting facts regarding potential violation eu antitrust laws janssencilag preparing response statement objections april janssen pharmaceuticals inc jpi received letter requesting certain documents united states department justice relating marketing promotion doribax jpi provided documents continues cooperate government inquiry may acclarent inc acclarent received subpoena united states attorney 's office district massachusetts requesting documents broadly relating sales marketing promotion acclarent relieva stratus microflow spacer products acclarent cooperating united states attorney 's office responding subpoena august depuy orthopaedics inc depuy inc depuy synthes inc depuy synthes johnson johnson services inc received informal request united states attorney 's office district massachusetts civil division united states department justice production materials relating asr xl hip device government since made additional informal requests production documents device government investigating whether person entity submitted caused submitted false claims false statements affecting federal health care programs connection marketing use asr xl hip device depuy orthopaedics inc depuy synthes johnson johnson services inc voluntarily produced documents response government 's informal requests fully cooperating government 's civil investigation october johnson johnson contacted california attorney general 's office regarding multistate attorney general investigation marketing surgical mesh products hernia urogynecological purposes johnson johnson subsidiaries johnson johnson subsidiaries since entered tolling agreement states participating multistate investigation december therakos inc therakos formerly subsidiary johnson johnson part orthoclinical diagnostics inc ocd franchise received letter civil division united states attorney 's office eastern district pennsylvania informing therakos united states attorney 's office investigating sales marketing uvadex methoxsalen uvar xts system period present united states attorney 's office requested ocd johnson johnson preserve documents could relate investigation therakos subsequently acquired affiliate gores capital partners iii lp ocd johnson johnson retain certain liabilities may result investigation activity occurred prior sale therakos taken appropriate steps retain potentially relevant documents cooperate united states attorney 's office 's investigation respect activity recent years johnson johnson received numerous requests variety united states congressional committees produce information relevant ongoing congressional inquiries policy johnson johnson cooperate inquiries producing requested information general litigation starting july five lawsuits filed united states district court district new jersey various employers employee benefit plans funds seeking recover amounts paid risperdal plan participants general plaintiffs allege johnson johnson certain pharmaceutical subsidiaries engaged offlabel marketing risperdal violation federal new jersey rico statutes addition plaintiffs asserted various state law claims cases consolidated one case seeking class action status shortly thereafter one action voluntarily dismissed december court dismissed actions four remaining plaintiffs april johnson johnson annual report plaintiffs filed new consolidated class action johnson johnson janssen lp janssen pharmaceuticals inc march action dismissed april one plaintiffs filed notice appeal united states court appeals third circuit appeal dismissed july april orthoclinical diagnostics inc ocd received grand jury subpoena united states department justice antitrust division requesting documents information period beginning september present pertaining investigation alleged violations antitrust laws blood reagents industry ocd complied subpoena february ocd received letter antitrust division indicating closed investigation november june following public announcement ocd received grand jury subpoena multiple class action complaints filed ocd direct purchasers seeking damages alleged price fixing various cases consolidated pretrial purposes united states district court eastern district pennsylvania blood reagent antitrust litigation august district court granted motion filed plaintiffs class certification ocd requested interlocutory review class certification decision october appellate court granted ocd 's petition interlocutory review april putative class action lawsuit filed united states district court northern district california representatives nursing home residents estates johnson johnson omnicare inc omnicare unidentified companies individuals february plaintiffs filed second amended complaint asserting certain rebate agreements johnson johnson omnicare increased amount money spent pharmaceuticals nursing home residents violated sherman act california business professions code second amended complaint also asserted claim unjust enrichment plaintiffs sought multiple forms monetary injunctive relief johnson johnson moved dismiss second amended complaint march court granted motion entirety august dismissing claims asserted plaintiffs october court dismissed action prejudice plaintiffs filed notice appeal united states court appeals ninth circuit november february plaintiffs stipulated voluntary dismissal matter prejudice pursuant terms stipulation ninth circuit dismissed case entirety march starting may multiple complaints seeking class action certification related mcneil recalls filed mcneil consumer healthcare certain affiliates including johnson johnson united states district court eastern district pennsylvania northern district illinois central district california southern district ohio eastern district missouri consumer complaints allege generally purchasers various mcneil medicines owed monetary damages penalties paid premium prices defective medications rather less expensive alternative medications one complaint seeks certification nationwide class purchasers medicines whereas one complaint harvey case seeks certification class motrin ib purchasers missouri october judicial panel multidistrict litigation consolidated consumer complaints except harvey case consolidated march one lawsuit mcneil consumer healthcare et al marketing sales practices litigation pretrial proceedings united states district court eastern district pennsylvania january plaintiffs cases except harvey case filed consolidated amended civil consumer class action complaint cac naming additional parties claims july court granted motion johnson johnson dismiss cac without prejudice permitted plaintiffs file amended complaint within thirty days dismissal order august plaintiffs filed second amended civil consumer class action complaint sac july court granted johnson johnson 's motion dismiss sac prejudice separately september johnson johnson johnson johnson inc mcneil consumer healthcare division johnson johnson inc received notice civil claim filed nick field supreme court british columbia canada bc civil claim bc civil claim putative class action brought behalf persons reside british columbia purchased period september present one various mcneil infants ' children 's overthecounter medicines manufactured fort washington facility bc civil claim alleges defendants violated bc business practices consumer protection act canadian statutes common laws selling medicines allegedly safe andor effective comply canadian good manufacturing practices bc plaintiff served affidavits support class certification april defendants responding affidavits served june date hearing certification application yet scheduled september shareholder ronald monk filed lawsuit united states district court district new jersey seeking class certification alleging johnson johnson certain individuals including executive officers employees johnson johnson failed disclose number manufacturing facilities failed maintain current good manufacturing practices result price company 's stock declined significantly plaintiff seeks pursue remedies securities exchange act recover alleged economic losses december motion johnson johnson dismiss granted part denied part plaintiff moved court reconsider part december ruling defendants filed answers remaining claims amended complaint february case proceeding discoveryin may court denied plaintiff 's motion reconsideration september plaintiff filed second amended complaint johnson johnson moved dismiss plaintiff 's second amended complaint part april omj pharmaceuticals inc omj pr filed lawsuit united states united states district johnson johnson annual report court district puerto rico alleging overpayment federal income taxes tax years ended november november omj pr alleges internal revenue service erroneously calculated omj pr 's tax credits section tax code omj pr filed motion summary judgment united states filed cross motion summary judgment october court granted united states ' motion summary judgment denied omj pr 's motion summary judgment omj pr appealed decision omj pr loses lawsuit may face liability subsequent tax years august arbitration panel ruled mitsubishi tanabe pharma corporation tanabe janssen biotech inc 's jbi 's distributor remicade japan could seek modify proportion net sales revenue tanabe must remit jbi exchange distribution rights commercial supply remicade supply price tanabe commenced arbitration centocor ortho biotech inc jbi pursuant parties ' distribution agreement grants tanabe right distribute remicade japan certain parts asia jbi counterclaimed increase supply price hearing held november determine appropriate split revenue parties awaiting decision johnson johnson subsidiaries also parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund comparable state local foreign laws primary relief sought cost past andor future remediation shareholder derivative actions starting april number shareholder derivative lawsuits filed united states district court district new jersey certain current former directors officers johnson johnson johnson johnson named nominal defendant actions consolidated august one lawsuit johnson johnson derivativelitigation additionally september another shareholder derivative lawsuit filed michael wolin new jersey superior court certain current former directors officers johnson johnson johnson johnson named nominal defendant action well parties action stipulated shall stayed johnson johnson derivative litigation completely resolved shareholder derivative actions similar claims collectively assert variety alleged breaches fiduciary duties including among things defendants allegedly engaged approved failed remedy prevent defective medical devices improper pharmaceutical rebates improper offlabel marketing pharmaceutical medical device products violations current good manufacturing practice regulations resulted product recalls failed disclose aforementioned alleged misconduct company 's filings securities exchange act complaint seeks variety relief including monetary damages corporate governance reforms johnson johnson moved dismiss actions grounds inter alia plaintiffs failed make demand upon board directors september johnson johnson derivative litigation dismissed without prejudice leave file amended complaint johnson johnson filed report johnson johnson derivative litigation matter july prepared special committee board directors investigated allegations contained derivative actions number shareholder demand letters board received raising similar issues special committee assisted investigation independent counsel special committee 's report recommended johnson johnson reject shareholder demands take whatever steps necessary appropriate secure dismissal derivative litigation ii board directors create new regulatory compliance committee charged responsibility monitoring oversight company 's health care compliance quality compliance systems issues board directors johnson johnson unanimously adopted special committee 's recommendations april board directors created regulatory compliance government affairs committee august two shareholders submitted shareholder demand letters filed shareholder derivative lawsuits united states district court district new jersey naming various current former officers directors defendants challenging board 's rejection demands november court consolidated two cases copeland v prince johnson johnson secured extension time respond complaint two additional shareholder derivative lawsuits filed may united states district court district new jersey two shareholder derivative lawsuits filed new jersey superior court may august naming current directors johnson johnson defendants johnson johnson nominal defendant complaints allege breaches fiduciary duties related company 's compliance foreign corrupt practices act participation united nations iraq oil food program company suffered damages result alleged breaches defendants failed disclose alleged misconduct company 's filings securities exchange act plaintiffs seek monetary damages state court plaintiffs also seek corporate governance reforms federal lawsuits consolidated july jj fcpa derivative shareholder litigation amended consolidated complaint filed august october johnson johnson moved dismiss consolidated federal lawsuit grounds plaintiffs failed make demand upon board directors plaintiffs secured extension time respond motion state lawsuits consolidated november jjshareholder johnson johnson annual report derivative litigation consolidated complaint filed december january johnson johnson moved dismiss stay state lawsuits pending resolution federal lawsuit moved dismiss ground plaintiffs failed make demand board directors may court granted motion johnson johnson stay state lawsuits pending resolution jj fcpa derivative shareholder litigation july parties shareholder derivative cases pending federal court discussed specifically rejohnson johnson derivative litigation copeland v prince jj fcpa derivative shareholderlitigation filed stipulation settlement permanently resolve actions entirety october settlement approved court november notice appeal filed united states court appeals third circuit shareholder objected approval settlement district court grounds lawsuit settlement provide benefit company plaintiffs ' counsel requested excessive fee award june two shareholders submitted shareholder demand letter march new jersey building laborers annuity new jersey building laborers pension funds filed additional shareholder derivative lawsuit new jersey superior court naming various current former officers directors defendants also challenging board 's rejection demands shareholder derivative lawsuit purports allege claims subject settlement described parties action entered consent order staying action pending final approval settlement discussed november plaintiffs agreed voluntarily dismiss action september two additional shareholder derivative lawsuits filed united states district court district new jersey donovan spamer george leon family trust naming current directors one former director johnson johnson defendants johnson johnson nominal defendant lawsuits allege defendants breached fiduciary duties decisions respect compensation chief executive officer period defendants made misleading statements company 's annual proxy statements lawsuits voluntarily dismissed without prejudice similar lawsuit behalf george leon family trust refiled july lawsuit seeks variety relief including monetary damages injunctive relief corporate governance reforms settlement resolve potential claims board directors ' evaluation allegations ongoing restructuring cordis corporation subsidiary johnson johnson announced discontinuation clinical development program nevo sirolimuseluting coronary stent cessation manufacture marketing cypher cypher select plus sirolimuseluting coronary stents end company focus cardiovascular therapies significant patient needs exist result mentioned restructuring plan announced cordis corporation company recorded million related pretax charges approximately million pretax restructuring charges require cash payments million restructuring charges consists asset writeoffs million million related leasehold contract obligations expenses million asset writeoffs relate property plant equipment million intangible assets million inventory million recorded cost products sold cordis restructuring program substantially completed restructuring charge recorded medical devices diagnostics segment johnson johnson annual report report independent registered public accounting firm shareholders board directors johnson johnson opinion accompanying consolidated balance sheets related consolidated statements earnings statements comprehensive income statements equity statements cash flows present fairly material respects financial position johnson johnson subsidiaries december january results operations cash flows three years period ended december conformity accounting principles generally accepted united states america also opinion company maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso company 's management responsible financial statements maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying management 's report internal control financial reporting responsibility express opinions financial statements company 's internal control financial reporting based integrated audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audits obtain reasonable assurance whether financial statements free material misstatement whether effective internal control financial reporting maintained material respects audits financial statements included examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management evaluating overall financial statement presentation audit internal control financial reporting included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk audits also included performing procedures considered necessary circumstances believe audits provide reasonable basis opinions company 's internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles company 's internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company ii provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company iii provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition company 's assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate described management 's report internal control financial reporting management excluded synthes inc assessment internal control financial reporting december acquired company purchase business combination also excluded synthes inc audit internal control financial reporting synthes inc whollyowned subsidiary whose total assets total revenues represent approximately respectively related consolidated financial statement amounts year ended december pricewaterhousecoopers llp new york new york february johnson johnson annual report managements report internal control financial reporting section sarbanesoxley act management required assess effectiveness companys internal control financial reporting end fiscal year report based assessment whether companys internal control financial reporting effective management company responsible establishing maintaining adequate internal control financial reporting companys internal control financial reporting designed provide reasonable assurance reliability companys financial reporting preparation external financial statements accordance generally accepted accounting principles internal controls financial reporting matter well designed inherent limitations therefore internal control financial reporting determined effective provide reasonable assurance respect financial statement preparation may prevent detect misstatements moreover projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate companys management assessed effectiveness companys internal control financial reporting december making assessment company used criteria established committee sponsoring organizations treadway commission coso internal control integrated framework criteria areas control environment risk assessment control activities information communication monitoring companys assessment included extensive documenting evaluating testing design operating effectiveness internal controls financial reporting company acquired synthes inc consolidated subsidiaries synthes june synthes total assets primarily intangible assets goodwill total revenues represented approximately respectively related consolidated financial statements period ended december acquisition occurred june synthes previously subject requirements section sarbanesoxley act scope company 's assessment design effectiveness internal control financial reporting fiscal year excluded synthes exclusion accordance sec 's general guidance assessment recently acquired business may omitted scope year acquisition based companys processes assessment described management concluded december companys internal control financial reporting effective effectiveness companys internal control financial reporting december audited pricewaterhousecoopers llp independent registered public accounting firm stated report appears herein alex gorsky dominic j caruso chairman board directors vice president finance chief executive officer chief financial officer johnson johnson annual report summary operations statistical data dollars millions except per share amounts sales customers us sales customers international total sales cost products sold selling marketing administrative expenses research development expense inprocess research development interest income interest expense net portion capitalized income expense net restructuring earnings provision taxes income provision taxes income net earnings add net loss attributable noncontrolling interest net earnings attributable johnson johnson percent sales customers diluted net earnings per share common stock percent return average shareholders equity percent increase decrease previous year sales customers diluted net earnings per share supplementary balance sheet data property plant equipment net additions property plant equipment total assets longterm debt operating cash flow common stock information dividends paid per share shareholders equity per share market price per share yearend close average shares outstanding millions basic diluted employees thousands attributable johnson johnson johnson johnson annual report shareholder return performance set forth line graphs comparing cumulative total shareholder return companys common stock periods five years ten years ending december cumulative total return standard poors stock index standard poors pharmaceutical index standard poors health care equipment index graphs tables assume invested december december companys common stock standard poors stock index standard poors pharmaceutical index standard poors health care equipment index dividends reinvested year cumulative total shareholder return johnson johnson sp index sp pharmaceutical index sp healthcare equipment index johnson johnson annual report year cumulative total shareholder return johnson johnson sp index sp pharmaceutical index sp healthcare equipment index johnson johnson annual report exhibit subsidiaries johnson johnson new jersey corporation domestic international subsidiaries shown december certain us subsidiaries international subsidiaries named significant aggregate johnson johnson parent jurisdiction name subsidiary organization us subsidiaries acclarent inc delaware alza corporation delaware animas corporation delaware biosense webster inc california cna development llc delaware codman shurtleff inc new jersey cordis corporation florida cordis international corporation delaware cordis llc delaware depuy mitek holding corporation delaware depuy mitek llc massachusetts depuy orthopaedics inc indiana depuy products inc indiana depuy spine llc ohio depuy synthes sales inc massachusetts depuy synthes inc delaware diabetes diagnostics inc delaware ethicon endosurgery inc new jersey ethicon endosurgery llc delaware ethicon llc delaware ethicon us llc texas ethicon inc new jersey iso holding corp delaware jj holdings nevada inc nevada janssen alzheimer immunotherapy research development llc delaware janssen biotech inc pennsylvania janssen global services llc new jersey janssen oncology inc delaware janssen ortho llc delaware janssen pharmaceuticals inc pennsylvania janssen products lp new jersey janssen research development llc new jersey janssen scientific affairs llc new jersey janssen services llc new jersey janssen supply group llc pennsylvania janssencilag manufacturing llc delaware jjhc llc delaware jnj international investment llc delaware johnson johnson middle east inc new jersey johnson johnson consumer companies inc new jersey johnson johnson development corporation new jersey johnson johnson finance corporation new jersey johnson johnson health care systems inc new jersey johnson johnson international new jersey johnson johnson japan inc new jersey johnson johnson sales logistics company llc new jersey johnson johnson services inc new jersey johnson johnson urban renewal associates new jerseyjurisdiction name subsidiary organization johnson johnson vision care inc florida jom pharmaceutical services inc delaware lifescan llc delaware lifescan products llc delaware lifescan inc california mcneil consumer pharmaceuticals co new jersey mcneil healthcare llc delaware mcneil la llc delaware mcneil mmp llc new jersey mcneil nutritionals llc delaware mcneilppc inc new jersey mentor texas lp delaware mentor worldwide llc delaware micro typing systems inc florida micrus endovascular llc delaware middlesex assurance company limited vermont neutrogena corporation delaware nitinol development corporation california noramco inc georgia omj pharmaceuticals inc delaware omrix biopharmaceuticals inc delaware ortho biologics llc delaware orthoclinical diagnostics inc new york refresh holdings inc delaware rutan realty llc new jersey scios inc delaware sterilmed inc minnesota synthes usa products llc delaware synthes usa llc delaware synthes inc delaware anspach effort llc florida wellness prevention inc michigan international subsidiaries almaco holding ag switzerland apsis france apsis germany gmbh germany beijing dabao cosmetics co ltd china berna biotech korea corporation korea republic berna rhein bv netherlands biosense webster israel ltd israel cilag advanced technologies gmbh switzerland cilag ag switzerland cilag gmbh international switzerland cilag holding ag switzerland cilag pharmaceuticals gmbh switzerland cordis francejurisdiction name subsidiary organization cordis de mexico sa de cv mexico cordis europa nv netherlands cordis medizinische apparate gmbh germany corimmun gmbh germany crucell holland bv netherlands crucell nv netherlands crucell sweden ab sweden crucell switzerland ag switzerland depuy ireland ireland depuy france france depuy international holdings limited united kingdom depuy international limited united kingdom depuy medical private limited india depuy mitek sarl switzerland depuy motion sarl switzerland depuy orthopadie gmbh germany depuy uk holdings limited united kingdom ees holdings de mexico de rl de cv mexico ethicon france ethicon ireland ireland ethicon pr holdings ireland ethicon women 's health urology sarl switzerland ethnor farmaceutica sa venezuela fms future medical system sa switzerland gmed healthcare bvba belgium high wycombe property management limited united kingdom jc general services cvba belgium janssen alzheimer immunotherapy ireland janssen alzheimer immunotherapy holding limited ireland janssen biologics ireland ireland janssen biologics bv netherlands janssen cilag farmaceutica sa argentina janssen de mexico de rl de cv mexico janssen inc canada janssen infectious diseasesdiagnostics bvba belgium janssen korea ltd korea republic janssen pharmaceutica nv belgium janssen pharmaceutical ireland janssen pharmaceutical holdings ireland janssen pharmaceutical kk japan janssen rd ireland ireland janssencilag france janssencilag ab sweden janssencilag ag switzerland janssencilag bv netherlands janssencilag farmaceutica ltda brazil janssencilag farmaceutica lda portugal janssencilag gmbh germanyjurisdiction name subsidiary organization janssen cilag limited thailand janssencilag limited united kingdom janssencilag nv belgium janssencilag oy finland janssencilag pharma gmbh austria janssencilag pharmaceutical saci greece janssencilag pty ltd australia janssencilag spa italy janssencilag ca venezuela janssencilag sa spain janssencilag sa de cv mexico jc health care ltd israel jjc acquisition company bv netherlands johnson johnson china investment ltd china johnson johnson china ltd china johnson johnson hong kong limited hong kong johnson johnson ireland limited ireland johnson johnson new zealand limited new zealand johnson johnson philippines inc philippines johnson johnson proprietary limited south africa johnson johnson thailand ltd thailand johnson johnson ab sweden johnson johnson ag switzerland johnson johnson consumer thailand limited thailand johnson johnson consumer bv netherlands johnson johnson consumer holdings france france johnson johnson consumer services eame ltd united kingdom johnson johnson de argentina sac e argentina johnson johnson de chile sa chile johnson johnson de colombia sa colombia johnson johnson de mexico sa de cv mexico johnson johnson de venezuela sa venezuela johnson johnson del ecuador sa ecuador johnson johnson del peru sa peru johnson johnson brasil industria e comercio de produtos para saude ltda brazil johnson johnson european treasury company ireland johnson johnson finance limited united kingdom johnson johnson financial services gmbh germany johnson johnson gesellschaft mbh austria johnson johnson gmbh germany johnson johnson group holdings gmbh germany johnson johnson hellas commercial industrial sa greece johnson johnson holding gmbh germany johnson johnson inc canada johnson johnson industrial ltda brazil johnson johnson international financial services company ireland johnson johnson kk japan johnson johnson kft hungaryjurisdiction name subsidiary organization johnson johnson korea selling distribution limited liability company korea republic johnson johnson korea ltd korea republic johnson johnson limitada portugal johnson johnson limited india johnson johnson limited united kingdom johnson johnson llc russian federation johnson johnson luxembourg finance company sarl luxembourg johnson johnson management limited united kingdom johnson johnson medical china ltd china johnson johnson medical pty limited south africa johnson johnson medical shanghai ltd china johnson johnson medical suzhou ltd china johnson johnson medical bv netherlands johnson johnson medical gmbh germany johnson johnson medical korea limited korea republic johnson johnson medical limited united kingdom johnson johnson medical mexico sa de cv mexico johnson johnson medical nv belgium johnson johnson medical products gmbh austria johnson johnson medical pty ltd australia johnson johnson medical sa argentina johnson johnson medical spa italy johnson johnson medical scs venezuela johnson johnson middle east fzllc united arab emirates johnson johnson pacific pty limited australia johnson johnson poland sp z oo poland johnson johnson pte ltd singapore johnson johnson pty limited australia johnson johnson spa italy johnson johnson sdn bhd malaysia johnson johnson sihhi malzeme sanayi ticaret limited sirketi turkey johnson johnson swiss finance company limited united kingdom johnson johnson taiwan ltd taiwan johnson johnson vision care ireland ireland johnson johnson prodaja medicinskih farmacevtskih izdelkov doo slovenia johnson johnson sa spain johnson johnson sa de cv mexico johnson johnson sro czech republic latam international investment company ireland latam properties holdings ireland lifescan scotland limited united kingdom mcneil ab sweden mcneil gmbh co ohg germany mcneil healthcare uk limited united kingdom mcneil manufacturing pty ltd australia mcneil products limited united kingdom mcneil sweden ab swedenjurisdiction name subsidiary organization medos international sarl switzerland medos sarl switzerland mentor medical systems bv netherlands mentor medical systems cv netherlands obtech medical sarl switzerland omj ireland ireland omj pr holdings ireland omrix biopharmaceuticals ltd israel orthoclinical diagnostics france orthoclinical diagnostics united kingdom orthoclinical diagnostics gmbh germany orthoclinical diagnostics kk japan orthoclinical diagnostics nv belgium pt johnson johnson indonesia indonesia shanghai johnson johnson pharmaceuticals ltd china synthes shanghai medical trading co ltd china synthes suzhou medical co ltd china synthes australia pty ltd australia synthes canada ltd canada synthes colombia sas colombia synthes deutschland holding gmbh germany synthes finanz ag switzerland synthes gmbh germany synthes gmbh switzerland synthes holding ag switzerland synthes industria e comercio ltda brazil synthes kk japan synthes limited united kingdom synthes lux finance srl luxembourg synthes lux holding srl luxembourg synthes luxembourg srl luxembourg synthes medical private limited india synthes produktions gmbh switzerland synthes srl italy synthes tuttlingen gmbh germany synthesstratec sa spain tasmanian alkaloids pty ltd australia tibotecvirco comm va belgium turnbuckle investment company ireland vania expansion france xianjanssen pharmaceutical ltd chinaexhibit consent independent registered public accounting firm hereby consent incorporation reference registration statements form form johnson johnson report dated february relating financial statements effectiveness internal control financial reporting appears annual report shareholders incorporated annual report also consent incorporation reference report dated february relating financial statement schedule appears pricewaterhousecoopers llp new york new york february exhibit certification chief executive officer pursuant section sarbanesoxley act alex gorsky certify reviewed annual report fiscal year ended december report johnson johnson company based knowledge report contain untrue statement material fact omit state material fact necessary make statements made light circumstances statements made misleading respect period covered report based knowledge financial statements financial information included report fairly present material respects financial condition results operations cash flows company periods presented report companys certifying officers responsible establishing maintaining disclosure controls procedures defined exchange act rules ae de internal control financial reporting defined exchange act rules af df company designed disclosure controls procedures caused disclosure controls procedures designed supervision ensure material information relating company including consolidated subsidiaries made known us others within entities particularly period report prepared b designed internal control financial reporting caused internal control financial reporting designed supervision provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles c evaluated effectiveness companys disclosure controls procedures presented report conclusions effectiveness disclosure controls procedures end period covered report based evaluation disclosed report change companys internal control financial reporting occurred companys recent fiscal quarter companys fourth fiscal quarter case annual report materially affected reasonably likely materially affect companys internal control financial reporting companys certifying officers disclosed based recent evaluation internal control financial reporting companys auditors audit committee companys board directors persons performing equivalent functions significant deficiencies material weaknesses design operation internal control financial reporting reasonably likely adversely affect companys ability record process summarize report financial information b fraud whether material involves management employees significant role companys internal control financial reporting alex gorsky chief executive officer date february exhibit b certification chief financial officer pursuant section sarbanesoxley act dominic j caruso certify reviewed annual report fiscal year ended december report johnson johnson company based knowledge report contain untrue statement material fact omit state material fact necessary make statements made light circumstances statements made misleading respect period covered report based knowledge financial statements financial information included report fairly present material respects financial condition results operations cash flows company periods presented report companys certifying officers responsible establishing maintaining disclosure controls procedures defined exchange act rules ae de internal control financial reporting defined exchange act rules af df company designed disclosure controls procedures caused disclosure controls procedures designed supervision ensure material information relating company including consolidated subsidiaries made known us others within entities particularly period report prepared b designed internal control financial reporting caused internal control financial reporting designed supervision provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles c evaluated effectiveness companys disclosure controls procedures presented report conclusions effectiveness disclosure controls procedures end period covered report based evaluation disclosed report change companys internal control financial reporting occurred companys recent fiscal quarter companys fourth fiscal quarter case annual report materially affected reasonably likely materially affect companys internal control financial reporting companys certifying officers disclosed based recent evaluation internal control financial reporting companys auditors audit committee companys board directors persons performing equivalent functions significant deficiencies material weaknesses design operation internal control financial reporting reasonably likely adversely affect companys ability record process summarize report financial information b fraud whether material involves management employees significant role companys internal control financial reporting dominic j caruso chief financial officer date february exhibit certification chief executive officer pursuant section sarbanesoxley act undersigned alex gorsky chief executive officer johnson johnson new jersey corporation company pursuant usc adopted pursuant section sarbanesoxley act hereby certifies best knowledge company 's annual report fiscal year ended december report fully complies requirements section securities exchange act information contained report fairly presents material respects financial condition results operations company alex gorsky chief executive officer dated february certification furnished sec report pursuant section sarbanesoxley act shall except extent required act deemed filed company purposes section securities exchange act amended otherwise subject liability sectionexhibit b certification chief financial officer pursuant section sarbanesoxley act undersigned dominic j caruso chief financial officer johnson johnson new jersey corporation company pursuant usc adopted pursuant section sarbanesoxley act hereby certifies best knowledge company 's annual report fiscal year ended december report fully complies requirements section securities exchange act information contained report fairly presents material respects financial condition results operations company dominic j caruso chief financial officer dated february certification furnished sec report pursuant section sarbanesoxley act shall except extent required act deemed filed company purposes section securities exchange act amended otherwise subject liability sectionexhibit cautionary statement pursuant private securities litigation reformact safe harbor forward looking statements company may time time make certain forwardlooking statements publiclyreleased materials written oral forwardlooking statements relate strictly historical current facts anticipate results based managements plans subject uncertainty forwardlooking statements may identified use words plans expects anticipates estimates words similar meaning conjunction among things discussions future operations financial performance companys strategy growth product development regulatory approvals market position expenditures forwardlooking statements based current expectations future events company guarantee forwardlooking statement accurate although company believes reasonable expectations assumptions investors realize underlying assumptions prove inaccurate unknown risks uncertainties materialize actual results could vary materially companys expectations projections investors therefore cautioned place undue reliance forwardlooking statements furthermore company undertake update forwardlooking statements result new information future events developments important factors could cause companys actual results differ companys expectations forwardlooking statements follows economic factors including inflation fluctuations interest rates currency exchange rates potential effect fluctuations revenues expenses resulting margins competitive factors including technological advances achieved patents attained competitors well new products introduced competitors challenges companys patents competitors allegations companys products infringe patents third parties could potentially affect companys competitive position ability sell products question require payment past damages future royalties particular generic drug firms filed abbreviated new drug applications seeking market generic forms companys key pharmaceutical products prior expiration applicable patents covering products event company successful defending resulting lawsuits generic versions product issue introduced resulting substantial market share revenue losses financial distress bankruptcies experienced significant customers suppliers could impair ability case may purchase companys products pay products previously purchased meet obligations company supply arrangements changes behavior spending patterns purchasers health care products services including delaying medical procedures rationing prescription medications reducing frequency physician visits foregoing health care insurance coverage result prolonged global economic downturn impact international operations financial instability international economies sovereign risk possible imposition governmental controls unstable international governments legal systems interruptions breaches computer communications systems including computer viruses hacking cyberattacks could impair company 's ability conduct business communicate internally customers result theft trade secrets misappropriation assets otherwise compromise privacy sensitive information belonging company customers business partners health care changes us countries resulting pricing pressures including continued consolidation among health care providers trends toward managed care health care cost containment shift towards governments becoming primary payers health care expenses government laws regulations relating sales promotion reimbursement pricing generally government laws regulations affecting us international operations including relating securities laws compliance trade monetary fiscal policies taxes price controls regulatory approval new products licensing patent rights environmental protection conflict minerals possible drug reimportation legislation competition research involving development improvement new existing products processes particularly significant results time time product process obsolescence developmentof new improved products important companys success areas business challenges difficulties inherent product development including potential inability successfully continue technological innovation complete clinical trials obtain regulatory approvals united states internationally gain maintain market approval products possibility encountering infringement claims competitors respect patent intellectual property rights preclude delay commercialization product significant litigation government action adverse company including product liability claims patent infringement claims antitrust claims increased scrutiny health care industry government agencies state attorneys general resulting investigations prosecutions carry risk significant civil criminal penalties including limited debarment government business difficulties delays manufacturing internally within supply chain cause voluntary involuntary business interruptions shutdowns product shortages substantial modifications business practices operations withdrawals suspensions current products market possible civil penalties criminal prosecution product liability insurance products may limited cost prohibitive unavailable product efficacy safety concerns whether based scientific evidence resulting product withdrawals recalls regulatory action part fda international counterparts declining sales impact business combinations including acquisitions divestitures company well externally pharmaceutical medical devices diagnostics consumer industries changes global climate extreme weather natural disasters could affect demand company 's products services cause disruptions manufacturing distribution networks alter availability goods services within supply chain affect overall design integrity company 's products operations reliance global supply chains production distribution processes complex subject increasing regulatory requirements may adversely affect sourcing supply pricing materials used products may involve multiple third parties require significant capital expenditures subject lengthy regulatory approvals possibility internal revenue service could assert one contrary positions challenge transactions consummated connection acquisition synthes inc tax perspective challenged amount total purchase price synthes shares could treated subject applicable us tax approximately statutory rate company plus interest impact political economic conditions due terrorist attacks us parts world us military action overseas well instability financial markets could result terrorism military actions issuance new revised accounting standards financial accounting standards board securities exchange commission foregoing list sets forth many factors could impact upon companys ability achieve results described forwardlooking statements investors understand possible predict identify factors consider list complete statement potential risks uncertainties company identified factors list permitted private securities litigation reform act